ZA200609809B - Solid dosage form of wetted heparin - Google Patents
Solid dosage form of wetted heparin Download PDFInfo
- Publication number
- ZA200609809B ZA200609809B ZA200609809A ZA200609809A ZA200609809B ZA 200609809 B ZA200609809 B ZA 200609809B ZA 200609809 A ZA200609809 A ZA 200609809A ZA 200609809 A ZA200609809 A ZA 200609809A ZA 200609809 B ZA200609809 B ZA 200609809B
- Authority
- ZA
- South Africa
- Prior art keywords
- heparin
- pharmaceutical composition
- solid pharmaceutical
- wetted
- molecular weight
- Prior art date
Links
- 229920000669 heparin Polymers 0.000 title claims description 314
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims description 294
- 229960002897 heparin Drugs 0.000 title claims description 266
- 239000007909 solid dosage form Substances 0.000 title claims description 16
- 239000000203 mixture Substances 0.000 claims description 158
- 239000008194 pharmaceutical composition Substances 0.000 claims description 156
- 239000007787 solid Substances 0.000 claims description 137
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 claims description 114
- 239000002775 capsule Substances 0.000 claims description 92
- 238000000034 method Methods 0.000 claims description 60
- 229940124447 delivery agent Drugs 0.000 claims description 53
- 239000003055 low molecular weight heparin Substances 0.000 claims description 51
- 229940127215 low-molecular weight heparin Drugs 0.000 claims description 51
- 239000007903 gelatin capsule Substances 0.000 claims description 44
- 239000002552 dosage form Substances 0.000 claims description 29
- 239000000080 wetting agent Substances 0.000 claims description 25
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 23
- 206010047249 Venous thrombosis Diseases 0.000 claims description 22
- 230000036470 plasma concentration Effects 0.000 claims description 22
- 208000007536 Thrombosis Diseases 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 15
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 14
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 229920002567 Chondroitin Polymers 0.000 claims description 10
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 10
- 229920001499 Heparinoid Polymers 0.000 claims description 10
- 239000002554 heparinoid Substances 0.000 claims description 10
- 229940025770 heparinoids Drugs 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- 125000004450 alkenylene group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000000732 arylene group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229960002446 octanoic acid Drugs 0.000 claims description 4
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- GCVGCXMTCJMBHY-UHFFFAOYSA-N 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid Chemical compound OC(=O)CCCNC(=O)C1=CC=C(Cl)C=C1O GCVGCXMTCJMBHY-UHFFFAOYSA-N 0.000 claims description 2
- XRTHAPZDZPADIL-UHFFFAOYSA-N 8-[(5-chloro-2-hydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1O XRTHAPZDZPADIL-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 73
- 238000011282 treatment Methods 0.000 description 60
- -1 monosodium salt Chemical class 0.000 description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- 230000000694 effects Effects 0.000 description 35
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 34
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 28
- 238000005469 granulation Methods 0.000 description 27
- 230000003179 granulation Effects 0.000 description 27
- 241000282560 Macaca mulatta Species 0.000 description 24
- 239000000499 gel Substances 0.000 description 24
- 229920001223 polyethylene glycol Polymers 0.000 description 24
- 239000002202 Polyethylene glycol Substances 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 23
- 235000014113 dietary fatty acids Nutrition 0.000 description 23
- 239000000194 fatty acid Substances 0.000 description 23
- 229930195729 fatty acid Natural products 0.000 description 23
- 241000282693 Cercopithecidae Species 0.000 description 22
- 239000007788 liquid Substances 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 19
- 239000000725 suspension Substances 0.000 description 19
- 239000013543 active substance Substances 0.000 description 18
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 17
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 16
- 229960001008 heparin sodium Drugs 0.000 description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 210000000214 mouth Anatomy 0.000 description 16
- 239000008213 purified water Substances 0.000 description 15
- 239000008187 granular material Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 229960005062 tinzaparin Drugs 0.000 description 14
- 239000000122 growth hormone Substances 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 239000004359 castor oil Substances 0.000 description 12
- 239000004094 surface-active agent Substances 0.000 description 12
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 11
- 229940088710 antibiotic agent Drugs 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 235000019438 castor oil Nutrition 0.000 description 11
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 11
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 11
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 10
- 125000005456 glyceride group Chemical group 0.000 description 10
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 10
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 239000004141 Sodium laurylsulphate Substances 0.000 description 9
- 229930182558 Sterol Natural products 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229910001220 stainless steel Inorganic materials 0.000 description 9
- 150000003432 sterols Chemical class 0.000 description 9
- 235000003702 sterols Nutrition 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 102000003982 Parathyroid hormone Human genes 0.000 description 8
- 108090000445 Parathyroid hormone Proteins 0.000 description 8
- 229920002125 Sokalan® Polymers 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000000199 parathyroid hormone Substances 0.000 description 8
- 229960001319 parathyroid hormone Drugs 0.000 description 8
- 230000003285 pharmacodynamic effect Effects 0.000 description 8
- 239000010935 stainless steel Substances 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 7
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 7
- 239000004698 Polyethylene Substances 0.000 description 7
- 229920003082 Povidone K 90 Polymers 0.000 description 7
- 108090000190 Thrombin Proteins 0.000 description 7
- 230000002785 anti-thrombosis Effects 0.000 description 7
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 229920000573 polyethylene Polymers 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000011321 prophylaxis Methods 0.000 description 7
- 231100000628 reference dose Toxicity 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 229960004072 thrombin Drugs 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Chemical class OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108010088847 Peptide YY Proteins 0.000 description 6
- 102100029909 Peptide YY Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000004019 antithrombin Substances 0.000 description 6
- 235000019700 dicalcium phosphate Nutrition 0.000 description 6
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000003801 milling Methods 0.000 description 6
- 239000000600 sorbitol Chemical class 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108060001064 Calcitonin Proteins 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 238000012084 abdominal surgery Methods 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 229940049964 oleate Drugs 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920005862 polyol Polymers 0.000 description 5
- 150000003077 polyols Chemical class 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 239000003488 releasing hormone Substances 0.000 description 5
- 238000001223 reverse osmosis Methods 0.000 description 5
- XUHVCHNJCBBXMP-UHFFFAOYSA-M sodium;10-[(2-hydroxybenzoyl)amino]decanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCCCC([O-])=O XUHVCHNJCBBXMP-UHFFFAOYSA-M 0.000 description 5
- 239000003549 soybean oil Substances 0.000 description 5
- 235000012424 soybean oil Nutrition 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000009747 swallowing Effects 0.000 description 5
- 238000005809 transesterification reaction Methods 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 102000055006 Calcitonin Human genes 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 208000005189 Embolism Diseases 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 4
- 229960004015 calcitonin Drugs 0.000 description 4
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 4
- 239000002285 corn oil Substances 0.000 description 4
- 235000005687 corn oil Nutrition 0.000 description 4
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 4
- 229960000958 deferoxamine Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 3
- 206010002388 Angina unstable Diseases 0.000 description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 description 3
- 229940122361 Bisphosphonate Drugs 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 101800001982 Cholecystokinin Proteins 0.000 description 3
- 102100025841 Cholecystokinin Human genes 0.000 description 3
- 108010013198 Daptomycin Proteins 0.000 description 3
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229940062527 alendronate Drugs 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 229940125684 antimigraine agent Drugs 0.000 description 3
- 239000002282 antimigraine agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 150000004663 bisphosphonates Chemical class 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 229940107137 cholecystokinin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 3
- 229960002286 clodronic acid Drugs 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 3
- 229960005484 daptomycin Drugs 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- ZZFKAZHZSSJSSE-UHFFFAOYSA-L disodium;[(cycloheptylamino)-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate;hydrate Chemical compound O.[Na+].[Na+].OP(O)(=O)C(P([O-])([O-])=O)NC1CCCCCC1 ZZFKAZHZSSJSSE-UHFFFAOYSA-L 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 229940009626 etidronate Drugs 0.000 description 3
- 229910021485 fumed silica Inorganic materials 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000002695 general anesthesia Methods 0.000 description 3
- 229940087068 glyceryl caprylate Drugs 0.000 description 3
- 229940074046 glyceryl laurate Drugs 0.000 description 3
- 208000037824 growth disorder Diseases 0.000 description 3
- 229920001903 high density polyethylene Polymers 0.000 description 3
- 239000004700 high-density polyethylene Substances 0.000 description 3
- 238000011540 hip replacement Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 229950006971 incadronic acid Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 108010010648 interferon alfacon-1 Proteins 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 238000013150 knee replacement Methods 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 229940070765 laurate Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000003346 palm kernel oil Substances 0.000 description 3
- 235000019865 palm kernel oil Nutrition 0.000 description 3
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 3
- 229940046231 pamidronate Drugs 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000012429 release testing Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 208000004043 venous thromboembolism Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical class CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000640882 Condea Species 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 206010014522 Embolism venous Diseases 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- 108010029961 Filgrastim Proteins 0.000 description 2
- 206010055690 Foetal death Diseases 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000004547 Glucosylceramidase Human genes 0.000 description 2
- 108010017544 Glucosylceramidase Proteins 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 102100030704 Interleukin-21 Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 229930195725 Mannitol Chemical class 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 102400000050 Oxytocin Human genes 0.000 description 2
- 101800000989 Oxytocin Proteins 0.000 description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
- 102100022831 Somatoliberin Human genes 0.000 description 2
- 101710142969 Somatoliberin Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 230000002402 anti-lipaemic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229960005348 antithrombin iii Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229960004588 cilostazol Drugs 0.000 description 2
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 229960000265 cromoglicic acid Drugs 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical class CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 229940113088 dimethylacetamide Drugs 0.000 description 2
- 229960002768 dipyridamole Drugs 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 229960004177 filgrastim Drugs 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 2
- 229940080812 glyceryl caprate Drugs 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229940015872 ibandronate Drugs 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 229940090438 infergen Drugs 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000000594 mannitol Chemical class 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 2
- 229950011129 minodronic acid Drugs 0.000 description 2
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 2
- 229950010733 neridronic acid Drugs 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
- 229960001723 oxytocin Drugs 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical class OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 2
- 229940051201 quinoline yellow Drugs 0.000 description 2
- 235000012752 quinoline yellow Nutrition 0.000 description 2
- FZUOVNMHEAPVBW-UHFFFAOYSA-L quinoline yellow ws Chemical compound [Na+].[Na+].O=C1C2=CC=CC=C2C(=O)C1C1=NC2=C(S([O-])(=O)=O)C=C(S(=O)(=O)[O-])C=C2C=C1 FZUOVNMHEAPVBW-UHFFFAOYSA-L 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 229940089617 risedronate Drugs 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 2
- 239000007892 solid unit dosage form Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 2
- 230000009424 thromboembolic effect Effects 0.000 description 2
- 229940019375 tiludronate Drugs 0.000 description 2
- 229940064689 tinzaparin sodium Drugs 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229960002647 warfarin sodium Drugs 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- WJTCHBVEUFDSIK-NWDGAFQWSA-N (2r,5s)-1-benzyl-2,5-dimethylpiperazine Chemical compound C[C@@H]1CN[C@@H](C)CN1CC1=CC=CC=C1 WJTCHBVEUFDSIK-NWDGAFQWSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- AOWCOHYBGYRYGE-UHFFFAOYSA-N 1-[2,3-bis(2-oxopropoxy)propoxy]propan-2-one Chemical compound CC(=O)COCC(OCC(C)=O)COCC(C)=O AOWCOHYBGYRYGE-UHFFFAOYSA-N 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- OEZPKXDBWNXBRE-UHFFFAOYSA-N 2,3-bis(2-hydroxyethoxy)propyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(OCCO)COCCO OEZPKXDBWNXBRE-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- MQFYRUGXOJAUQK-UHFFFAOYSA-N 2-[2-[2-(2-octadecanoyloxyethoxy)ethoxy]ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOC(=O)CCCCCCCCCCCCCCCCC MQFYRUGXOJAUQK-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- PPPFYBPQAPISCT-UHFFFAOYSA-N 2-hydroxypropyl acetate Chemical compound CC(O)COC(C)=O PPPFYBPQAPISCT-UHFFFAOYSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- DUIOKRXOKLLURE-UHFFFAOYSA-N 2-octylphenol Chemical class CCCCCCCCC1=CC=CC=C1O DUIOKRXOKLLURE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VLGDSNWNOFYURG-UHFFFAOYSA-N 4-propyloxetan-2-one Chemical compound CCCC1CC(=O)O1 VLGDSNWNOFYURG-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 239000001534 FEMA 4201 Substances 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 206010058279 Factor V Leiden mutation Diseases 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- HDIFHQMREAYYJW-XGXNLDPDSA-N Glyceryl Ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-XGXNLDPDSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020608 Hypercoagulation Diseases 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 206010065973 Iron Overload Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical class CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 101000800755 Naja oxiana Alpha-elapitoxin-Nno2a Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 241001483078 Phyto Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Chemical class 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001744 Sodium fumarate Substances 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- XZAGBDSOKNXTDT-UHFFFAOYSA-N Sucrose monopalmitate Chemical compound CCCCCCCCCCCCCCCC(O)=O.OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(CO)O1 XZAGBDSOKNXTDT-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- XJLATMLVMSFZBN-VYDXJSESSA-N actinonin Chemical compound CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO XJLATMLVMSFZBN-VYDXJSESSA-N 0.000 description 1
- XJLATMLVMSFZBN-UHFFFAOYSA-N actinonine Natural products CCCCCC(CC(=O)NO)C(=O)NC(C(C)C)C(=O)N1CCCC1CO XJLATMLVMSFZBN-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960003616 bemiparin Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000013194 cardioversion Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229940018872 dalteparin sodium Drugs 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- KZGQGOXKCBISME-UHFFFAOYSA-J dicalcium;disulfate Chemical compound [Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O KZGQGOXKCBISME-UHFFFAOYSA-J 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- UYAAVKFHBMJOJZ-UHFFFAOYSA-N diimidazo[1,3-b:1',3'-e]pyrazine-5,10-dione Chemical compound O=C1C2=CN=CN2C(=O)C2=CN=CN12 UYAAVKFHBMJOJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 108010015174 exendin 3 Proteins 0.000 description 1
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 1
- 235000019240 fast green FCF Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 231100000562 fetal loss Toxicity 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940074047 glyceryl cocoate Drugs 0.000 description 1
- 229940116338 glyceryl ricinoleate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
- 235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Chemical class 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Chemical class 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003358 interferon alfacon-1 Drugs 0.000 description 1
- 229940074383 interleukin-11 Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 229940037959 monooctanoin Drugs 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- YZUUTMGDONTGTN-UHFFFAOYSA-N nonaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCO YZUUTMGDONTGTN-UHFFFAOYSA-N 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical class CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- YYZUSRORWSJGET-UHFFFAOYSA-N octanoic acid ethyl ester Natural products CCCCCCCC(=O)OCC YYZUSRORWSJGET-UHFFFAOYSA-N 0.000 description 1
- ITIXDWVDFFXNEG-JHOUSYSJSA-N olcegepant Chemical compound C([C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCN(CC1)C=1C=CN=CC=1)NC(=O)N1CCC(CC1)N1C(NC2=CC=CC=C2C1)=O)C1=CC(Br)=C(O)C(Br)=C1 ITIXDWVDFFXNEG-JHOUSYSJSA-N 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229940077412 peg-12 laurate Drugs 0.000 description 1
- 229940008456 peg-32 oleate Drugs 0.000 description 1
- 238000013146 percutaneous coronary intervention Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229940097941 polyglyceryl-10 laurate Drugs 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Chemical class 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Chemical class 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-M pravastatin(1-) Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-M 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 238000011324 primary prophylaxis Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 229940116423 propylene glycol diacetate Drugs 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229960002917 reteplase Drugs 0.000 description 1
- 108010051412 reteplase Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940005573 sodium fumarate Drugs 0.000 description 1
- 235000019294 sodium fumarate Nutrition 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940032085 sucrose monolaurate Drugs 0.000 description 1
- 229940035023 sucrose monostearate Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- IWXIJAJPTFEKPL-UHFFFAOYSA-H tricalcium trisulfate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O IWXIJAJPTFEKPL-UHFFFAOYSA-H 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
SOLID DOSAGE FORM OF WETTED HEPARIN
[11 This application claims the benefit of U.S. Provisional Application No. 60/569,475, filed May 6, 2004, U.S. Provisional Application No. 60/572,679, filed May 19, 2004, and U.S. Provisional Application No. 60/598,978, filed August 4, 2004, all of which are hereby incorporated by reference.
[2] The present invention relates to a solid dosage form of wetted heparin and a delivery agent.
[3] Heparin is the most widely used anticoagulant for the prevention and initial treatment of venous thromboembolism, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). PE is estimated to result in more than 300,000 hospital admissions per year and is responsible for approximately 50,000 to 250,000 deaths annually in the United
States alone. There are numerous indications approved and unapproved that involve use of heparin products, both fractionated and unfractioned. Usually, the goal of the therapy is to treat or prevent a thrombotic event.
[4] Heparin is a potent anticoagulant whose chemical composition includes a mixture of repeating disaccharide units, composed of glucosamine and either L-iduronic or D- glucuronic acid. Heparin is a naturally occurring glycosaminoglycan most frequently isolated commercially from cow lung and porcine intestinal mucosa. It is sulfated, anionic, and highly acidic. '
[5] Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots also known as thrombus. It inhibits several activated coagulation factors, in particular, factor Xa and factor Ila, by binding to the plasma protease inhibitor antithrombin III. It is partially metabolized by desulphation and depolymerization.
[6] Heparin includes both unfractionated and low-molecular-weight heparin, e.g., dalteparin sodium, enoxaparin, tinzaparin. Heparins are indicated for prophylaxis of ischemic complications in unstable angina and non-Q-wave mycordial infarction, prophylaxis of deep vein thrombosis (DVT) in patients following hip or knee replacement surgery, and prophylaxis of DVT in patients following abdominal surgery in patients at risk for thromboembolic complications. Abdominal surgery patients at risk include those who are over 40 years of age, obese, undergoing surgery under general anesthesia lasting longer than 30 minutes or who have additional risk factors such as malignancy or a history of DVT or pulmonary embolism. Heparins are also indicated for prophylaxis of DVT in medical patients with severely restricted mobility during acute illness, and treatment of DVT with or without pulmonary embolism. [77 The anticoagulant effect of heparin requires the presence of antithrombin
II to facilitate the formation of a 1:1 complex with thrombin. The rate of thrombin-antithrombin
III complex formation is increased 1,000-fold by heparin which serves as a catalytic template to which both the inhibitor and thrombin bind. Binding of heparin also induces a conformational change in antithrombin, making the reactive site more accessible to thrombin. Antithrombin binds to heparin via sulfate groups on a specific pentasaccharide sequence found in about 30% of heparin molecules. The heparin-antithrombin III complex can also inhibit activated Factors IX,
X, XI, and XII. Once thrombin binds to antithrombin, the heparin molecule is released from the complex. When, for example, the concentration of heparin in plasma is about 0.1 to 1.0 IU/mL, thrombin, Factor Ila, and Factor Xa are rapidly inhibited by antithrombin ITI. The result is an increase in blood coagulation time, as measured by activated partial thromboplastin time (aPTT), thrombin time, anti-Factor Iia, and anti-Factor Xa activity. (81 Presently, heparin is administered parenterally, either by continuous or intermittent intravenous infusion or by deep subcutaneous injection. Heparin alone is not well absorbed through the gastrointestinal tract.
[9] U.S. Patent No. 6,458,383 disclses a delayed release pharmaceutical dosage form for oral administration of a hydrophilic drug. The dosage form comprises low molecular weight heparin, a bile salt or bile acid, and at least one surfactant selected from hydrophilic surfactant, a lipophilic surfactant, and mixtures thereof.
[10] There remains a need for heparin pharmaceutical compositions that can be administered orally and provide an increased heparin response, i.e., an oral heparin administration that can traverse the gastrointestinal tract and provide increased bioavailability.
Such a composition would provide a more convenient dosage method for patients receiving heparin. Oral heparin would also increase patient compliance, particularly for patients requiring prophylactic therapy to prevent major venous thromboembolic events. The fact that injections . | i 3 h
) s and needles are not required is appealing to patients and can reduce infections due to the disruption of the integrity of the skin by injections.
[11] The present invention relates to a solid pharmaceutical composition comprising a delivery agent and wetted heparin. The inclusion of wetted heparin rather than un- wetted heparin in the solid pharmaceutical composition results in increased delivery of the heparin. Without being bound by any particular theory, applicants believe that because the polymer chain of the wetted heparin is already in an “open” form, while un-wetted heparin is not, : less of the wetted heparin is broken down in the gastrointestinal tract and is more readily absorbed in the stomach. The solid pharmaceutical composition may be a unit dosage form, such as a tablet, capsule, orally disintegrating tabs and strips, granules, powder packets, and patches.
[12] According to one preferred embodiment, the solid pharmaceutical composition comprises (i) a delivery agent selected from N-[8-(2-hydroxybenzoyl)- amino]caprylic acid and pharmaceutically acceptable salts thereof (such as its monosodium salt) (collectively hereafter referred to as “SNAC™), and (ii) wetted heparin. The wetted heparin comprises heparin and a solvent. Preferably, the solvent also partially solubilizes the SNAC.
The un-solubilized SNAC has been found to act as a good gelling agent for gelling the SNAC and wetted heparin together. The solid pharmaceutical compositions facilitates the oral delivery of heparin, with increased bioavailability compared to the administration of tablets containing an equivalent amount of un-wetted heparin and SNAC.
’
[13] Yet another embodiment of the invention is a method for administering or facilitating the delivery of heparin in a subject in need thereof by orally administering the solid pharmaceutical composition of the present invention.
[14] Yet another embodiment is a method of treating or preventing thrombosis in a subject in need thereof by orally administering 4n anti-thrombosis effective amount of the solid pharmaceutical composition of the present invention. Any type of thrombosis can be treated or prevented with the pharmaceutical composition including, but not limited to, deep vein thrombosis (DVT) and pulmonary embolism (PE).
[15] Yet another embodiment is a method of preventing a major venous "thromboembolic event in a subject in need thereof by orally administering an anti-thrombosis effective amount of the solid pharmaceutical composition of the present invention. Such patients include those who recently (e.g., within about a week or two) underwent hip or knee replacement or abdominal surgery, especially those who are over 40 years of age, or obese, or underwent surgery under general anesthesia lasting longer than 30 minutes, or have additional risk factors, such as malignancy or a history of DVT or PE.
[16] Yet another embodiment is a method of preparing a solid pharmaceutical composition of the present invention by mixing a delivery agent, heparin, and wetting agent to form a semi solid or gel composition. For example, a blend of delivery agent and heparin can be added to a wetting agent solution (individually or collectively) to form a semi-solid or gel composition. The solid pharmaceutical composition may further be formulated into a unit dosage form, such as by packing the composition into a capsule.
[17] Yet another embodiment is a solid pharmaceutical composition comprising a delivery agent (e.g., SNAC), and wetted heparin, wherein:
‘, . ; ¢)) about 120 minutes after oral administration of the solid pharmaceutical composition to a human, the human exhibits a plasma aPTT, an anti-factor IIa plasma concentration, an anti-factor Xa plasma concentration, or any combination of the foregoing that are statistically significantly greater than that about 120 minutes after oral administration of an identical composition containing unwetted heparin instead of wetted heparin, 2) after oral administration of the solid pharmaceutical composition to a human, the human exhibits an Emax for aPTT, EAUC(0-inf) for aPTT, Emax for anti-factor Ila, EAUC(0- inf) for anti-factor Ila, Emax for anti-factor Xa, EAUC(0-inf) for anti-factor Xa, or any combination of the foregoing that are statistically significantly greater than after oral administration of an identical composition containing unwetted heparin instead of wetted heparin, or €)) both.
[18] Yet another embodiment is a solid pharmaceutical composition comprising SNAC and wetted heparin, wherein: 09) about 120 minutes after oral administration of the solid pharmaceutical composition to a human, the human exhibits one or more of the following: (i) a plasma aPTT of at least about 38 seconds, (ii) an anti-factor Ila plasma concentration of at least about 0.11 IU/ml, or (iii) an anti-factor Xa plasma concentration of at least about 0.1 IU/ml, 2) after oral administration of the solid pharmaceutical composition to a human, the human exhibits one or more of the following: (i) an Emax for aPTT of at least about 50 IU/ml, (ii) an EAUC(0-inf) for aPTT of at least about 80 IU * hr/ml,
(iii) an Emax for anti-factor Ila of at least about 0.35 IU/ml, (iv) an EAUC(0-inf) for anti-factor Ila of at least about 0.7 TU * hr/ml, (v) an Emax for anti-factor Xa of at least about 0.35 IU/ml, (vi) an EAUC(0-inf) for anti-factor Xa of at least about 0.68 IU * hr/ml, or 3) both. '
[19] Preferably, about 120 minutes after administration, the human exhibits (i) a plasma aPTT of at least about 39 or about 50 seconds, (ii) an anti-factor Ila plasma concentration of at least about 0.2 IU/ml, (iii) an anti-factor Xa plasma concentration of at least about 0.2 IU/ml, or any combination thereof. Preferably, after administration, the human exhibits (i) an EAUC(0-inf) for aPTT of at least about 100, 150, or 180 IU * hr/ml, (ii) Emax for anti-factor Ila of at least about 0.4 IU/ml, (iii) an EAUC(0-inf) for anti-factor IIa of at least about 1.0 IU * hr/ml, (iv) an Emax for anti-factor Xa of at least about 0.4 IU/ml, (v) an EAUC(0-inf) for anti-factor Xa of at least about 1.0 IU * hr/ml, of any combination thereof.
[20] Yet another embodiment is a method of treating or preventing DVT in a human in need thereof by orally administering one or more solid pharmaceutical compositions comprising SNAC and wetted heparin, wherein 1) about 120 minutes after oral administration of the solid pharmaceutical composition to a human, the human exhibits one or more of the following: (i) a plasma aPTT of at least 38 seconds, (ii) an anti-factor Ila plasma concentration of at least about 0.11 IU/ml, or (iii) an anti-factor Xa plasma concentration of at least about 0.1 IU/ml, 2) after oral administration of the solid pharmaceutical composition to a human, the human exhibits one or more of the following:
(1) an Emax for aPTT of at least about 50 IU/ml, (ii) an EAUC(0-inf) for aPTT of at least about 80 IU * hr/ml, (iii) an Emax for anti-factor Ila of at least about 0.35 IU/ml, (iv) an EAUC(0-inf) for anti-factor IIa of at least about 0.7 IU * hr/ml, - (v) an Emax for anti-factor Xa of at least about 0.35 IU/ml, (vi) an EAUC(0-inf) for anti-factor Xa of at least about 0.68 IU * hr/ml, or 3) both. :
[21] Preferably, about 120 minutes after administration, the human exhibits (i) a plasma aPTT of at least about 39 or 50 seconds, (ii) an anti-factor Ila plasma concentration of at least about 0.2 IU/ml, (iii) an anti-factor Xa plasma concentration of at least about 0.2 IU/ml, or any combination thereof. Preferably, after administration, the human exhibits (i) an EAUC(0- inf) for aPTT of at least about 100, 150, or 180 IU * hr/ml, (ii) Emax for anti-factor Ila of at least about 0.4 IU/ml, (iii) an EAUC(0-inf) for anti-factor IIa of at least about 1.0 IU * hr/ml, (iv) an
Emax for anti-factor Xa of at least about 0.4 IU/ml, (v) an EAUC(0-inf) for anti-factor Xa of at least about 1.0 TU * hr/ml, of any combination thereof.
[22] Yet another embodiment of the present invention is a solid heparin pharmaceutical composition comprising a delivery agent and wetted heparin, where, upon oral administration of the composition after 15 days of storage at ambient conditions, the maximum ‘Antifactor Xa concentration achieved is at least 66% or 75% of that achieved with the } composition before storage.
[23] The present invention also relates to a solid pharmaceutical composition comprising a delivery agent and wetted heparin, wherein the un-wetted heparin has a particle size of less than about 180 microns, or less than about 120 microns, or less than about 80 microns. Also provided is a method of preparing a solid pharmaceutical composition comprising mixing heparin having an average particle size of less about 180 microns, or less than about 120 microns, or less than about 80 microns, a wetting agent, and a delivery agent.
[24] The present invention also relates to a solid pharmaceutical composition ) comprising a delivery agent and wetted heparin in a suspension, wherein the average particle size of particles the suspension is less than about 180 microns, or less than about 120 microns, or less than about 80 microns. Also provided is a method of preparing a solid pharmaceutical composition comprising mixing wetted heparin and a delivery agent to form a suspension in a solvent, and milling the suspension to provide a suspension with an average particle size of less than about 180 microns, or less than about 120 microns, or less than about 80 microns.
[25] Figure 1 is a graph of Anti-Factor Xa activity (IU/ml) versus time after administration of each of the pharmaceutical compositions of Example 1 and Comparative
Examples 1-4.
[26] Figure 2 is a graph of Anti-Factor Ila activity uy ml) versus time after administration of each of the pharmaceutical compositions of Example 1 and Comparative
Examples 1-4.
[27] Figure 3 isa graph of Antifactor Xa activity (IU/ml) versus time after administration of a capsule having the formulation shown in Table 15a (Example 3) or Table 1 (Example 1) to Rheses monkeys (1 capsule/monkey).
[28] Figure 4 is a graph of Antifactor Xa activity (IU/ml) versus time after administration of the capsules described in Example 6 to Cynos monkeys (1 capsule/monkey).
[29] Figure 5 is a graph of Antifactor Xa activity (IU/ml) versus time after administration of the capsules described in Example 7 to Rhesus monkeys (1 capsule/monkey).
[30] Figure 6 is a graph of Antifactor Xa activity (IU/ml) versus time after administration of the capsules described in Example 8 to Rhesus monkeys (1 capsule/monkey).
[31] Figure 7 is an overlay of Figures 5 and 6.
[32] Figure 8 is a graph of Antifactor Xa activity (FU/ml) versus time after administration of the capsules described in Example 9 to Rhesus monkeys (1 capsule/monkey).
[33] Figure 9 is a graph of Antifactor Xa activity (IU/ml) and aPTT versus time after administration of the capsules described in Example 10 to Rhesus monkeys (1 capsule/monkey).
[34] Figure 10 is a graph of Antifactor Xa activity (IU/ml) and aPTT versus time after administration of the capsules described in Example 11 to Rhesus monkeys (1 capsule/monkey).
[35] Figure 11 is a graph of Antifactor Xa activity (IU/ml) versus time after administration of the capsules described in Example 12 to Rhesus monkeys (1 capsule/monkey).
[36] Figures 12 and 13 are graphs of Antifactor Xa activity (IU/ml) and aPTT versus time after administration of the capsules described in Example 13 after storage for 15 days at 40 °C and 75% relative humidity (Fig. 12) or 25 °C and 60% relative humidity (Fig. 13) to Rhesus monkeys (1 capsule/monkey). [371 Figures 14 and 15 are graphs of Antifactor Xa activity versus time after administration of the capsules described in Example 13 before and after 15 days of storage at 40
°C and 75% relative humidity or 25°C and 60% relative humidity for fifteen days to Rhesus monkeys (1 capsule/monkey).
[38] Figures 16, 17, 18, 19, and 20 are graphs of aPTT times, Antifactor Ila,
Antifactor Xa, and plasma SNAC concentrations versus time for healthy males administered the treatment arms described in Example 14.
[39] Figures 21 and 22 is a dissolution profile of the formulation set forth in
Tables 35a and 35b, and prepared as described in Example 15.
[40] Figure 23 is a graph of Antifactor Xa activity versus time for beagles administered the formulations described in Tables 35a and 35b, and prepared as described in
Example 15, administered as described in Example 17.
[41] Figure 24 is a graph of Antifactor Xa activity versus time for Rhesus monkeys administered the formulations described in Tables 35a and 35b, and prepared as described in Example 15, administered as described in Example 18.
[42] Figure 25 is a graph of Antifactor Xa activity versus time for beagles administered the formulations described in Tables 35a and 35b, and prepared as described in
Example 15, administered as described in Example 19.
[43] As used herein and in the appended claims, the singular forms "a," "an," and "the," include plural referents unless the context clearly indicates otherwise. Thus, for example, reference to "a molecule" includes one or more of such molecules, "a reagent” includes one or more of such different reagents, and reference to "the method" includes reference to equivalent steps and methods known to those of ordinary skill in the art that could be modified or substituted for the methods described herein.
[44] The term “wetted heparin” as used herein refers to a form of heparin where the individual heparin particles or molecules are completely or partially surrounded by a solvent or mixture of solvents (also referred to as a "wetting agent"). The heparin may or may not be dissolved in the wetting agent. Without being bound by any particular theory, itis believed that the wetting agent remains within the interstices of the heparin polymer chain in wetted heparin (without necessarily dissolving the heparin) and thereby results in faster dissolution of the heparin upon administration. Preferably, the delivery agent is in intimate contact with the wetted heparin in the solid pharmaceutical composition.
[45] The term “heparin” as used herein refers to all forms of heparin, including, but not limited to, unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin (e.g., tinzaparin (including tinzaparin sodium)), very low molecular weight heparin, and ultra low molecular ‘weight heparin. Non-limiting examples include unfractionated heparin, such as heparin sodium (e.g., heparin sodium USP, available from Scientific Protein
Labs of Waunakee, WI). Heparin generally has a molecular weight of from about 1,000 or 5,000 to about 30,000 Daltons. The term “low molecular weight heparin” generally refers to heparin in which at least about 80% (by weight) of the heparin and has a molecular weight of between about 3000 and about 9000 daltons. Non-limiting examples of low molecular weight heparin include tinzaparin, enoxaprin, and daltiparin. Tinzaparin has been approved by the U.S. Food &
Drug Administration for the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin sodium. The sodium salt of tinazaparin is available under the trademark Innohep™ from Pharmion . -12- } y
Corporation of Boulder, CO. The term “very low molecular weight heparin” generally refers to heparin in which at least about 80% (by weight) of the heparin has a molecular weight of between about 1500 and about 5000 daltons. A non-limiting example of very low molecular weight heparin is bemiparin. The term “ultra low molecular weight heparin” generally refers to heparin in which at least about 80% (by weight) of the heparin has a molecular weight of : between about 1000 and about 2000 daltons. A non-limiting examples of ultra low molecular weight heparin is fondiparinux.
[46] The term “polymorph” refers to a crystallographically distinct form of a substance.
[47] The term “hydrate” as used herein includes, but is not limited to, (i) a substance containing water combined in the molecular form and (ii) a crystalline substance containing one or more molecules of water of crystallization or a crystalline material containing free water.
[48] Unless otherwise specified, the term “SNAC” as used herein refers to N- (8-[2-hydroxybenzoyl]-amino) caprylic acid and pharmaceutically acceptable salts thereof, including its monosodium salt. The term “SNAC free acid” refers to N-(8-[2-hydroxybenzoyl]- amino) caprylic acid. Unless otherwise noted, the term “SNAC” refers to all forms of SNAC, including all amorphous and polymorphic forms of SNAC, such as those described in U.S.
Provisional Application No. 60/569,476 filed May 6, 2004 and U.S. Provisional Application No. 60/619,418, filed October 15, 2004.
[49] The term “SNAD” as used herein refers to N-(8-{2-hydroxybenzoyl]- amino) decanoic acid and pharmaceutically acceptable salts thereof, including its monosodium salt. Unless otherwise noted, the term “SNAD” refers to all forms of SNAD, including all amorphous and polymorphic forms of SNAD.
[50] The term “SNAC trihydrate” as used herein refers to a crystalline form of monosodium SNAC in which three molecules of water are associated with each molecule of
SNAC. '
[51] The term “solvate” as used herein includes, but is not limited to, a molecular or ionic complex of molecules or ions of a solvent with molecules or ions of delivery agent.
[52] The term “delivery agent” refers to any of the delivery agent compounds disclosed or incorporated by reference herein, including their pharmaceutically acceptable salts.
[53] An “effective amount of heparin” is an amount of heparin which is effective to treat or prevent a condition in a subject to whom it is administered over some period of time, e.g., provides a therapeutic effect during a desired dosing interval. Effective doses will vary, as recognized by those skilled in the art, depending on excipient usage and the possibility of co-usage with other agents for treating a condition.
[54] An "effective amount of the pharmaceutical composition” is an amount of the pharmaceutical composition described which is effective to treat or prevent a condition in a subject to whom it is administered over some period of time, e.g., provides a therapeutic effect during a desired dosing interval.
[55] The term “treat”, “treating”, or “treated” refers to prophylactically preventing, curing, healing, alleviating, relieving, altering, remedying, ameliorating, improving, or affecting a condition (e.g., a disease), the symptoms of the condition, or the predisposition toward the condition.
[56] An “effective amount of delivery agent” is an amount of the delivery agent which promotes the absorption of a desired amount of the heparin.
[57] The term "subject" includes mammals, such as rodents, cows, pigs, dogs, cats, primates, and particularly humans.
[58] The term “AUC” as used heréin, means area under the plasma concentration-time curve, as calculated by the trapezoidal rule over the complete dosing interval, e.g., 24-hour interval.
[59] The term “mean”, when preceding a pharmacokinetic value (e.g., mean
Peak), represents the arithmetic mean value of the pharmacokinetic value unless otherwise specified.
[60] As used herein, the term “about” means within 10% of a given value, preferably within 5%, and more preferably within 1% of a given value. Alternatively, the term “about” means that a value can fall within a scientifically acceptable error range for that type of value, which will depend on how qualitative a measurement can be given by the available tools.
[61] “Indication” means the use for which the drug is administered either to prevent or to treat a condition, and may be used interchangeably with “treat”, “treated” or “treating”. :
[62] “Thrombus” refers to a clot, or the tendency to form a clot caused by any one of numerous events in vivo or in vitro.
[63] “Thrombotic Event” and Thromboebolic Complications,” refer to the formation of a thrombus.
[64] “Antilipidemic Drugs” means any drug or agent that can lower all forms of serum cholesterol and/or triglycerides.
[65] “A control aPTT value” means the aPTT value in seconds used by those skilled in the art to compare a patient’s serum-aPTT value to an untreated value.
Delivery Agents .
[66] Delivery agents which may bé used in the pharmaceutical composition of the present invention include those having the formula:
R* ©
CL NT
R? OH " ©
R1 wherein
RY, R% R?, and R* are independently hydrogen, -OH, -NR°R’, halogen, C;-C4 alkyl, or
C;-C4 alkoxy;
RS is a substitued or unsubstituted C,-Cj¢ alkylene, substituted or unsubstituted C,-Cie alkenylene, substituted or unsubstituted C;-C)z alkyl(arylene), or substituted or unsubstituted aryl(C;-C,; alkylene); and
R® and R’ are independently hydrogen, oxygen, or C-C; alkyl.
[67] The term "substituted" as used herein includes, but is not limited to, substitution with any one or any combination of the following substituents: halogens, hydroxide,
C1-Cq alkyl, and C,-C,4 alkoxy.
[68] The terms "alkyl", "alkoxy", "alkylene", "alkenylene", "alkyl(arylene)", and "aryl(alkylene)" include, but are not limited to, linear and branched alkyl, alkoxy, alkylene, alkenylene, alkyl(arylene), and aryl(alkylene) groups, respectively.
“7 Wo 2005107773 PCT/US2005/016012
[69] Preferred delivery agents include, but are not limited to, SNAC, SNAD, 8- (N-2-hydroxy-5-chlorobenzoyl)aminocaprylic acid, 8-(N-2-hydroxy-4-methoxybenzoyl)- aminocaprylic acid, 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid, and pharmaceutically acceptable salts thereof.
[70] Other suitable delivery agents for the present invention are described in
U.S. Patent Nos. 6,846,844, 6,699,467, 6,693,208, 6,693,073, 6,663,898, 6,663,887, 6,646,162, 6,642,411, 6,627,228, 6,623,731, 6,610,329, 6,558,706, 6,525,020, 6,461,643, 6,461,545, 6,440,929, 6,428,780, 6,413,550, 6,399,798, 6,395,774, 6,391,303, 6,384,278, 6,375,983, 6,358,504, 6,346,242, 6,344,213, 6,331,318, 6,313,088, 6,245,359, 6,242,495, 6,221,367, 6,180,140, 5,541,155, 5,693,338, 5,976,569, 5,643,957, 5,955,503, 6,100,298, 5,650,386, 5,866,536, 5,965,121, 5,989,539, 6,001,347, 6,071,510, and 5,820,881. Delivery agents of the present invention are also described in U.S. Patent Application Publication Nos. 20050009748, 20040110839, 20040106825, 20040068013, 20040062773, 20040022856, 20030235612, 20030232085, 20030225300, 20030198658, 20030133953, 20030078302, 20030072740, 20030045579, 20030012817, 20030008900, 20020155993, 20020127202, 20020120009, 20020119910, 20020102286, 20020065255, 20020052422, 20020040061, 20020028250, 20020013497, 20020001591, 20010039258, and 20010003001. Delivery agents of the present invention are also described in International Publication Nos. WO 2005/020925,
WO 2004/104018, WO 2004/080401, WO 2004/062587, WO 2003/057650, WO 2003/057170,
WO 2003/045331, WO 2003/045306, WO 2003/026582, WO 2002/100338, WO 2002/070438,
WO 2002/069937, WO 02/20466, WO 02/19969, WO 02/16309, WO 02/15959, WO 02/02509,
WO 01/92206, WO 01/70219, WO 01/51454, WO 01/44199, WO 01/34114, WO 01/32596,
WO 01/32130, WO 00/07979, WO 00/59863, WO 00/50386, WO 00/47188, WO 00/40203, and
WO
-17 -
AMENDED SHEET
96/30036. Each of the above listed U.S. patents and U.S. and International published applications are herein incorporated by reference. These delivery agents may be prepared by methods known in the art, such as those described in the aforementioned patents and published patent applications. For example, SNAC may be prepared by methods known in the art, such as those described in U.S. Patent Nos. 5,650,386 and 5,866,536, and U.S. Patent Application
Publication No. 2002/0065255.
[71] The delivery agent may be purified by recrystallization or by fractionation on one or more solid chromatographic supports, alone or linked in tandem. Suitable recrystallization solvent systems include, but are not limited to, acetonitrile, methanol, and tetrahydrofuran. Fractionation may be performed (i) on a suitable chromatographic support such as alumina, using methanol/n-propanol mixtures as the mobile phase, (ii) by reverse phase chromatography using trifluoroacetic acid/acetonitrile mixtures as the mobile phase, or (iii) by ion exchange chromatography using water or an appropriate buffer as the mobile phase. When anion exchange chromatography is performed, preferably a 0-500 mM sodium chloride gradient is employed.
[72] Furthermore, the delivery agents of the present invention may be in a salt form. Non-limiting examples of pharmaceutically acceptable salts include sodium, hydrochloric acid, sulfuric acid, phosphoric acid, citric acid, acetic acid, sulfate, phosphate, chloride, bromide, iodide, acetate, propionate, hydrobromic acid, sodium hydroxide, potassium hydroxide, ammonium hydroxide, and potassium carbonate. These salts can be prepared by methods known in the art. For example, sodium salts may be prepared by dissolving the delivery agent in ethanol and adding aqueous sodium hydroxide.
a ts
[73] The amount of delivery agent in the solid pharmaceutical composition is a delivery agent effective amount and can be determined for the particular heparin composition by methods known to those skilled in the art.
[74] According to one embodiment of the invention, the pharmaceutical composition includes from about 50 to about S00 mg of SNAC. According to another embodiment, the pharmaceutical composition includes from about 215 to about 245 mg of
SNAC.
[75] The ratio of delivery agent to heparin (mg to USP heparin units) in the pharmaceutical composition generally ranges from about 1:20 to about 1:400. Accordingtoa preferred embodiment, the ratio ranges from about 1:65 to about 1:150.
[76] The weight ratio of heparin to delivery agent in the pharmaceutical composition generally ranges from about 1:1 to about 1:10. According to a preferred embodiment, the weight ratio ranges from about 1:1 or 1:2.5 to about 1:5 or about 1:7.5, or about 1:2.5 to about 1:10, or about 1:5 to about 1:10 heparin:delivery agent.
Heparin
[77] The pharmaceutical composition can include a therapeutic effective amount of heparin. Alternatively, the amount can be less than a therapeutic amount when (ia dosage form containing a plurality of pharmaceutical compositions is used, or (ii) a plurality of the pharmaceutical compositions are intended to be administered concurrently and, in total, contain a therapeutic effective amount.
[78] The total amount of heparin to be used can be determined by methods known to those skilled in the art. However, because the compositions of the invention may deliver heparin more efficiently than other compositions or compositions containing the heparin alone, lower amounts of heparin than those used in prior dosage unit forms or delivery systems can be administered to the subject, while still achieving the same blood levels and/or therapeutic effects. .
[79] According to one embodimerit of the invention, the pharmaceutical composition includes from about 10 to about 500 mg of heparin. According to another embodiment, the pharmaceutical composition includes from about 100 to about 115 mg of heparin. According to yet another embodiment, the pharmaceutical composition includes from about 2,000 to about 50,000 USP heparin units. According to yet another embodiment, the pharmaceutical composition includes from about 10,000 to about 20,000 USP heparin units.
According to yet another embodiment, the pharmaceutical composition includes from about 12,000 to about 18,000 USP heparin units.
[80] A preferred type of heparin is unfractionated heparin.
Wetting Agent
[81] The wetting agent can be a liquid which solubilizes the heparin and is present within the interstices of the polymer chain of the heparin. Because such a wetting agent solubilizes the heparin, it is also a solvent in the pharmaceutical composition. According to one preferred embodiment, the pharmaceutical composition includes a sufficient amount of wetting agent to partially solubilize the delivery agent. According to another embodiment, the wetting agent and the solvent or solubilizer may be different agents, or they may be the same.
[82] Suitable wetting agents include, but are not limited to, alcohols, polyols, hydroxylated fatty acid esters (i.e., fatty acid esters having one or more hydroxy groups), and non-hydroxylated fatty acid esters (i.e., fatty acid esters that do not have hydroxy groups). Non- limiting examples of suitable solvents include ethanol, ethylene glycol, propylene glycol, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives, PEG-40 hydrogenated castor oil (available as
Cremophor® RH 40 from BASF Ag of Ludwigshafen, Germany), medium chain (Cg-C,, fatty acids) triglycerides (available as Labrafac® CC from Gattefossé Corporation of Paramus, NJ), oleoyl macrogol-6 glycerides (Labrafil® M 1944 CS available from Gattefossé Corporation), linoleoyl macrogol-6 glycerides (Labrafil® M 2125 CS available from Gattefossé Corporation), propylene glycol monolaurate (Lauroglycol® 90 available from Gattefossé Corporation), caprylic/capric glycerides (Imwitor® 742 available from Sasol Germany GmbH of Witten,
Germany), glyceryl cocoate (Imwitor® 928 available from Sasol Germany GmbH), glyceryl caprylate (Imwitor® 988 available from Sasol Germarny GmbH), propylene glycol dicaprylate/dicaprate (Miglyol® 840 from Condea Vista Co. of Cranford, NJ), glyceryl ricinoleate (Softigen® 701 available from Sasol Germarny GmbH), PEG-6 caprylic/capric glycerides (Softigen® 767 available from Sasol Germany GmbH), bis-diglycerylpolyacyladipate (Softigen® 645 available from Sasol Germarny GmbH), PEG-25 trioleate (Tagat® TO available from Goldschmidt Chemical Corp, Hopewell, Va.), polysorbate 80 (Tween 80), ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000 (such as tetrahydrofurfuryl alcohol PEG ether (glycofurol (BASF of Ludwigshafen, Germany, under the trademark Tetraglycol™)) or methoxy PEG (Union Carbide of Midland, Michigan)), amides and other nitrogen-containing compounds (such as 2-pyrrolidone, 2-piperidone, } -caprolactam, N- alkylpyrrolidone, N-hydroxyalkyl-pyrrolidone, N-alkylpiperidone, N-alkylcaprolactam,
dimethylacetamide and polyvinyl-pyrrolidone), esters (such as ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, 3 -caprolactone and isomers thereof, A-valerolactone and isomers thereof, and B-butyrolactone and isomers thereof), other solubilizers known in the art (such as dimethyl acetamide, dimethyl isosorbide, N- methyl pyrrolidones, monooctanoin, and diethylene glycol monoethyl ether), and mixtures thereof, Other suitable wetting agents are referred to as solubilizers in U.S. Patent No. 6,458,383, which is hereby incorporated by reference.
[83] Preferred wetting agents include, but are not limited to, polyethylene glycol having a molecular weight less than about 800 daltons (e.g., polyethylene glycol-300), propylene glycol monocaprylate (such as Capmul® PGS (fatty acid distribution by GLC: <1.0%
Ce, >98.0% Cs, <2.0% Co, and <1.0% C,; and higher) from Abitec Corporation of Columbus,
Ohio; and Capryol 90 (containing 90% monoesters) from Gattefosse Corp., Paramus, NJ), and mixtures thereof. When capsules which dissolve upon contact with water are used, the pharmaceutical composition within the capsule preferably is substantially free of water (e.g., includes less than about 8, about 5, or about 1% by weight of water (based on 100% total weight of pharmaceutical composition)) or is free of water.
[84] According to one embodiment, the pharmaceutical composition includes polyethylene glycol-300.
[85] According to another embodiment, the pharmaceutical composition includes a mixture of polyethylene glycol-300 and propylene glycol monocaprylate.
[86] In yet another embodiment, the pharmaceutical composition includes from about 100 to about 500 mg polyethylene glycol-300, and about 20 to about 250 mg of propylene glycol monocaprylate. In yet another embodiment, the pharmaceutical composition includes from about 210 to about 240 mg polyethylene glycol-300 and from about 90 to about 110 mg propylene glycol monocaprylate.
[87] Generally, the ratio of wetting agent to heparin (mg to USP heparin units) in the pharmaceutical composition ranges from about 1:10 to about 1:100. According to a preferred embodiment, the ratio ranges from about 1:25 to about 1:60.
[88] The weight ratio of heparin to delivery agent in the pharmaceutical composition generally ranges from about 1:1 to about 1:10. According to a preferred embodiment, the weight ratio ranges from about 1:1 or 1:2.5 to about 1:5 or about 1:2.5 to about 1:10.
[89] The aforementioned wetting agents may be used in combination with an ancillary wetting agent, such as water, glyceryl caprylate/caprate (available as Capmul® MCM from Abitec Corporation of Columbus, Ohio), polysorbate 20, lauroyl macrogol-32 glyceride (Gelucire® 44/14 available from Gattefosse Corp., Paramus, NJ), stearoyl macrogol-32 glyceride (Gelucire® 50/13 available from Gattefosse Corp.), caprylic/capric triglyceride (available as
Akomed E and Akomed R from Karlshamns AB of Karlshamn, Sweden; as Captex® 355 from
Abitec Corporation of Columbus, Ohio; as Miglyol® 810 and 812 from Condea Vista Co. of
Cranford, NJ), and mixtures thereof.
Additional Active Ingredients and Additives
Additional Active Agents
[90] Suitable additional active agents include, but are not limited to, warfarin sodium. Other suitable active ingredients include, but are not limited to, acetylsalicylic acid
(ASA or aspirin), or enteric coated ASA, ticlodipine, clopidogrel, pentoxifyline, cilostazol, dipyridamole, ER- dipyridamole, abciximab, cilostazol, eptifibatide, or or tirofiban, either individually or in combination. Other suitable active agents include, but are not limited to thrombolytic agents, such as alteplase, reteplase, streptokinase, tenecteplase and urokinase, either alone or in combination. Other suitable active agents include, but are not limited to antilipidemic drugs, including but not limited to the statins such as lovastatin, atorvostatin, and , pravastatin, either individually or in combination. Other biologically active agents and chemically active agents, including, but not limited to, pharmacological agents and therapeutic agents can be added to solid dosage forms of the present invention.
[91] Suitable biologically and chemically active agents include, but are not limited to, proteins; polypeptides; peptides; hormones; polysaccharides, muco-polysaccharides and particularly mixtures of muco-polysaccharides; carbohydrates; lipids; small polar organic molecules (i.e. polar organic molecules having a molecular weight of 500 daltons or less); other organic compounds; and particularly compounds which by themselves do not pass (or which pass only a fraction of the administered dose) through the gastrointestinal mucosa and/or are susceptible to chemical cleavage by acids and enzymes in the gastrointestinal tract; or any combination thereof.
[92] Further examples of suitable biologically active agents include, but are not limited to, the following, including synthetic, natural or recombinant sources thereof: growth hormones, including human growth hormones (hGH), recombinant human growth hormones (thGH), bovine growth (hGH), bovine growth hormones, and porcine growth hormones; growth hormone-releasing hormones; growth hormone releasing factor (e.g., GRT analog g); interferons, including a, p and v; interleukin-1; interleukin-2; insulin, including porcine, bovine, human, and human recombinant, optionally havi goiter ions including zinc, sodium, calcium and ammonium; insulin-like growth factor, including IGF-1; heparin, including unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin and ultra low molecular weight heparin; calcitonin, including salmon, eel, porcine and human; erythropoietin: atrial naturetic factor; antigens; monoclonal antibodies; somatostatin; protease inhibitors; adrenocorticotropin, gonadotropin releasing hormone; oxytocin; leutinizing-hormone-releasing-hormone; follicle stimulating hormone; glucocerebrosidase; thrombopoietin; filgrastim; prostaglandins; cyclosporin; vasopressin; cromolyn sodium (sodium or disodium chromoglycate); vancomycin; desferrioxamine (DFO); bisphosphonates, including alendronate, tiludronate, etidronate, clodronate, pamidronate, olpadronate, and incadronate; parathyroid hormone (PTH), including its fragments; anti-migraine agents such as BIBN-4096BS and other calcitonin gene-related proteins antagonists; antimicrobials , including antibiotics (include gram-positive acting, bacteriocidal, lipopeptidal and cyclic peptidal antibiotics, including daptomycin), anti-bacterials and anti-fungal agents; vitamins; analogs, fragments, mimetics or polyethylene glycol (PEG)-modified derivatives of these compounds; or any combination thereof.
[93] Further examples include, but are not limited to, the following, including synthetic, natural or recombinant sources thereof: :
Antimicrobials, including Antibiotics, Anti-Bacterials and Anti-Fungal Agents; non- limiting examples of Antibiotics include Gram-Positive Acting, Bacteriocidal,
Lipopeptidal and Cyclic Peptidal Antibiotics, such as Daptomycin And Analogs thereof;
Anti-Migraine Agents such as BIBM.4096BS And Other Calcitonin Gene-Related To
Bisphosphonates, including Alendronate, Clodronate, Etidronate, Ibandronate,
Incadronate, Minodronate, Neridronate, Olpadronate, Pamidronate, Risedronate,
Growth Hormones, including Human Growth Hormones (hGH), Recombinant Human
Heparinoids, Dermatans, Chondroitins, Low Molecular Weight Heparin, Very Low
Molecular Weight Heparin Ultra Low Molecular Weight Heparin and synthetic heparins including Fondiparinux;
Insulin, including Porcine, Bovine, Human, And Human Recombinant, Optionally
Interferons, Including o (e.g., Interferon Alfacon-1 (Available As Infergen® From
Intermune, Inc. of Brisbane, Ca)), alpha, B, Omega and v;
Interleukin-1; Interleukin-2; Interleukin-11; Interleukin-21;
Leutinizing Hormone and Leutinizing Hormone Releasing Hormone;
Leptin (OB Protein); EE
Monoclonal Antibodies including Retuxin, TNF-alpha soluble receptors;
Parathyroid Hormone (PTH), including its fragments, including PTH 1-34 and PTH 1- 38;
Peptide YY (PYY) including PYY Agonists and PYY fragment 3-36;
Prostaglandins;
Protease Inhibitors; }
Thrombopoietin;
Vaccines including those against anthrax, Y. Pestis, Influenza, or Herpes; including secretagogues, analogs, fragments, mimetics or polyethylene glycol (PEG)-modified derivatives of these compounds; or any combination thereof.
[94] The pharmaceutical composition can include a therapeutic effective amount of any of the additional active agent(s). Alternatively, the amount can be less than a therapeutic amount when (i) a dosage form containing a plurality of pharmaceutical compositions is used, or (ii) a plurality of the pharmaceutical compositions are intended to be administered concurrently and, in total, contain a therapeutic effective amount.
[95] The total amount of active agent to be used can be determined by methods known to those skilled in the art. However, because the compositions of the invention may deliver active agents more efficiently than other compositions or compositions containing the active agent alone, lower amounts of the active than those used in prior dosage unit forms or delivery systems can be administered to the subject, while still achieving the same blood levels and/or therapeutic effects. .
Additives
[96] The solid pharmaceutical composition and unit dosage form of the present invention may include other active agents and pharmaceutically acceptable additives, such as excipients, carriers, diluents, stabilizers, plasticizers, binders, glidants, disintegrants, bulking agents, lubricants, plasticizers, colorants, film formers, flavoring agents, taste-masking agents, sugars, sweeteners, preservatives, dosing vehicles, surfactants, and any combination of any of the _ foregoing. Preferably, these additives are pharmaceutically acceptable additives, such as those described in Remington's, The Science and Practice of Pharmacy, (Gennaro, AR,, ed., 20% edition, 2003, Mack Pub. Co.), which is herein incorporated by reference.
[97] In one embodiment of the present invention, the pharmaceutical composition or solid unit dosage unit form is substantially free or completely free of carbomer.
According to another embodiment, the pharmaceutical composition or solid dosage form is substantially free or completely free of Carbopol® and/or the carbomer Carbopol® 934P.
[98] Suitable binders include, but are not limited to, starch, gelatin, sugars (such as sucrose, molasses and lactose), dibasic calcium phosphate dihydrate, natural and synthetic gums (such as acacia, sodium alginate, carboxymethyl cellulose, methyl cellulose, polyvinylpyrrolidone, polyethylene glycol, ethylcellulose, and waxes.
[99] Suitable glidants include, but are not limited to, talc and silicon dioxide (silica) (e.g, fumed silica and colloidal silicon dioxide).
[100] Suitable disintegrants include, but are not limited to, starches, sodium starch glycolate, croscarmellose sodium, crospovidone, clays, celluloses (such as purified - cellullose, methylcellulose, and sodium carboxymethyl cellulose), alginates, pregelatinized corn starches, and gums (such as agar; guar, locust bean, karaya, pectin and tragacanth gums). A preferred disintegrant is sodium starch glycolate.
[101] Suitable bulking agents include, but are not limited to, starches (such as rice starch), microcrystalline cellulose, lactose (e.g., lactose monohydrate), sucrose, dextrose, mannitol, calcium sulfate, dicalcium sulfate, and tricalcium sulfate.
[102] Suitable lubricants include, but are not limited to, stearic acid, stearates (such as calcium stearate and magnesium stearate), talc, boric acid, sodium benzoate, sodium acetate, sodium fumarate, sodium chloride, polyethylene glycol, hydrogenated cottonseed, and castor oils.
[103] Suitable surfactants include, but are not limited to, sodium lauryl sulfate, hydroxylated soy lecithin, polysorbates, and block copolymers of propylene oxide and ethylene oxide.
[104] Hydrophilic non-ionic surfactants and lipophilic surfactants as described in U.S. Patent No. 6,458,383, which is hereby incorporated by reference, can be included in the pharmaceutical composition and dosage form. Suitable hydrophilic non-ionic surfactants include, but are not limited to, alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyalkylene alkyl ethers such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethylene glycol alkyl phenols; polyoxyalkylene alkyl phenol fatty acid esters such as polyethylene glycol fatty acids monoesters and polyethylene glycol fatty acids diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters such as polyethylene glycol sorbitan fatty acid esters; hydrophilic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenatéd vegetable oils, fatty acids, and sterols; polyoxyethylene sterols, derivatives, and analogues thereof; polyoxyethylated vitamins and derivatives thereof; polyoxyethylene-polyoxypropylene block copolymers; and mixtures thereof.
[105] More specifically, hydrophilic surfactants that may be used in the present invention include, but are not limited to, PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG- 32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate,
PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG- glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate,
PEG-30 glyceryl oleate, PEG-30. glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil,
PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polyglyceryl-10 laurate, PEG- cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 steary! ether, tocopheryl PEG-100 succinate, PEG-24 cholesterol, polyglyceryl-10 oleate, Tween 40, Tween 60, sucrose monostearate, sucrose monolaurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series,
PEG 15-100 octyl phenol series, and poloxamers.
[106] Lipophilic surfactants include, but are not limited to, fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; propylene glycol fatty acid esters; sorbitan fatty acid esters; polyethylene glycol sorbitan fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; : polyethylene glycol alkyl ethers; sugar esters; sugar'ethers; lactic acid derivatives of mono- and di-glycerides; hydrophobic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols; oil-soluble vitamins/vitamin derivatives; and mixtures thereof. For example, the lipophilic surfactant can be one or more elycerol fatty acid esters, propylene glycol fatty acid esters, or a mixture thereof, or one or more hydrophobic transesterification products of a polyol with at least one member of the group consisting of vegetable oils, hydrogenated vegetable oils, and triglycerides.
[107] Among the lipophilic transesterification products, transesterification products of a polyol such as ethylene glycol, glycerol, propylene glycol, and sorbitol can be used. As is known in the art, a large number of surfactants of different degrees of hydrophobicity or hydrophilicity can be prepared by reaction of alcohols or polyalcohols with a variety of natural and/or hydrogenated oils. Most commonly, the oils used are castor oil or hydrogenated castor oil, or an edible vegetable oil such as corn oil, olive oil, peanut oil, palm kernel oil, apricot kernel oil, or almond oil. Alcohols include glycerol, propylene glycol, ethylene glycol, polyethylene glycol, maltol, sorbitol, and pentaerythritol. Among these alcohol-oil transesterified surfactants, hydrophobic surfactants include PEG-5 hydrogenated castor oil, PEG- 7 hydrogenated castor oil, PEG-9 hydrogenated castor oil, PEG-6 corn oil (Labrafil® M 2125 CS available from Gattefossé Corporation of Paramus, NJ), PEG-6 almond oil (Labrafil® M 1966
CS), PEG-6 apricot kernel oil (Labrafil® M 1944 CS), PEG-6 olive oil (Labrafil® M 1980 CS),
PEG-6 peanut oil (Labrafil® M 1969 CS), PEG-6 hydrogenated palm kernel oil (Labrafil® M 2130 BS), PEG-6 palm kernel oil (Labrafil® M 2130 CS), PEG-6 triolein (Labrafil® M 2735 CS),
PEG-8 corn oil (Labrafil® M WL.2609 BS), PEG-20 com glycerides (Crovol M40), and PEG-20 almond glycerides (Crovol A40).
[108] The pharmaceutical compositions and dosage forms may also include one or more enzyme inhibitors. Such enzyme inhibitors include, but are not limited to, compounds such as actinonin or epiactinonin and derivatives thereof. Other enzyme inhibitors include, but are not limited to, aprotinin (Trasylol) and Bowman-Birk inhibitor.
Dosage Forms
[109] The solid pharmaceutical composition of the present invention, which includes wetted heparin and a delivery agent, can be formulated as a solid unit dosage form. The dosage form can be, for example, a tablet, a sachet, or a capsule, such as a hard or soft gelatin capsule. The dosage form can provide immediate, sustained, or controlled release of the delivery agent, heparin, and optionally, additional active agents.
[110] The solid pharmaceutical composition and solid unit dosage form of the present invention can be prepared as follows. A delivery agent in solid form is processed (such as by milling through a 35-mesh screen) to provide a powder having a relatively small and preferably uniform particle size. The delivery agent is then blended with heparin, and optionally a filler and/or wetting agent with, for example, a V-blender or similar device, to provide a powder blend. | ‘
[111] Separately, a wetting agent mixture is prepared by mixing a wetting agent, heparin and a delivery agent. The mixture may also, for example, include water. The formulation of the wetting mixture is selected so as to wet the heparin when mixed with the aforementioned powder blend. According to one preferred embodiment, the wetting agent mixture is also formulated so as to partially solubilize the delivery agent when mixed with the powder blend. | :
[112] The powder blend is added to the wetting agent mixture in small increments under continuous mixing. Mixing is continued for a sufficient time (e.g., 15 minutes) after all of the powder blend has been added to obtain a uniform composition. The resulting composition is typically a semi-solid, gel, or liquid.
[113] The composition may then be formulated into a dosage form, such as a capsule, by methods known in the art. According to one preferred embodiment, the resulting composition is packed into a soft gelatin capsule or hard gelatin capsule (e.g., Size 0 Licap
Capsugel Hard Gelatin capsules). Other suitable methods are described in U.S. Patent Nos. 6,605,298, 6,458,383, 6,261,601, 5,714,477, and 3,510,561; U.S. Patent Application Publication
Nos. 2003/0077303 and 2001/0024658; and International Publication No. WO 88/10117, all of which are incorporated by reference. :
Uses
[114] The present invention provides a method for administering or facilitating the delivery of heparin to an animal by administering to a subject the solid pharmaceutical composition of the present invention. The subject is preferably a human. The person is v preferably a human in need thereof, or a human who would benefit from the administration of heparin.
[115] Another embodiment is a method of treating or preventing thrombosis in a subject in need thereof by orally administering an anti-thrombosis effective amount of the solid pharmaceutical composition of the present invention to the subject. Any type of thrombosis can be treated or prevented with the pharmaceutical composition including, but not limited to, deep vein thrombosis (DVT) and pulmonary embolism (PE).
[116] Another embodiment is a method of treating or preventing ischemic complications in unstable angina and/or non-Q-wave mycordial infarction in a subject in need thereof by orally administering an anti-thrombosis effective amount of the solid pharmaceutical composition of the present invention to the subject.
[117] Another embodiment is a method of treating or preventing deep vein thrombosis (DVT) in a subject following hip or knee replacement surgery by orally administering an anti-thrombosis effective amount of the solid pharmaceutical composition of the present invention to the subject. Yet, another embodiment is a method of treating or preventing DVT following abdominal surgery in patients at risk for thromboembolic complications by orally administering an anti-thrombosis effective amount of the solid pharmaceutical composition of the present invention to the subject. Abdominal surgery patients at risk include, but are not limited to, those who are over 40 years of age, obese, undergoing surgery under general anesthesia lasting longer than 30 minutes or who have additional risk factors such as malignancy or a history of DVT or pulmonary embolism.
[118] Another embodiment is a method of treating or preventing DVT in a subject with severely restricted mobility by orally administering an anti-thrombosis effective amount of the solid pharmaceutical composition of the present invention to the subject. Further embodiments include, but are not limited to the treatment of cardiac valve replacements, both mechanical and cadaver; treatment of endocarditis; prophylaxis in patients undergoing neurological procedures, such as,.but not limited to, resection of malignant brain tumors; prophylaxis in patients with acute spinal cord injury, medical conditions associated with thromboembolism, such as but not limited to, those with ischemic stroke or restricted mobility, cancer, myocardial infarction, cancer, congestive heart failure, or severe pulmonary disease; for secondary prophylaxis of venous thromboembolism during pregnancy, or for primary prophylaxis in pregnant women with inherited causes of thrombophilia (e.g. deficiencies in thrombin III, protein C, protein s, Factor V, Leiden mutation, prothrombin polymorphism, hyperhomocysteinemia); for embolisms associated with atrial fibrillation or those with concurrent prosthetic valves and atrial fibrillation; for cardioversion of atrial fibrillation or atrial flutter; for disseminated intravascular coagulation; to reduce the risk of complications in patents undergoing percutaneous coronary intervention, percutaneous transluminal coronary angioplasty, arthrectomy, coronary or other vessel stent implantation, ischemic cerbrovascular accident, hemodialysis, peripheral vascular interventions, acute myocardial infarction; unstable angina and non-ST-Segment Elevation Myocardial infarction; cerebral thromboembolism; complications of pregnancy, including but not limited to pregnancy loss in women with a history of antiphospholipid antibodies/ antiphospholipid syndrome with or without fetal loss, fetal death or fetal miscarriage. Other uses of heparin may be found in Drug Information, American Society of Health System Pharmacists, 2005, which is incorporated herein by reference.
[119] According to one embodiment, from about 50,000 to about 90,000 units of heparin (in compositions or dosage forms of the present invention) are administered one to five times daily (e.g., three times daily) to treat thrombosis. According to one preferred embodiment, each composition includes from about 250 mg to about 2.3 g of SNAC.
[120] Yet another embodiment of the present invention is a method for the treatment or prevention of a disease or for achieving a desired physiological effect, such as those listed in the table below, in an animal by administering the pharmaceutical composition of the present invention. The pharmaceutical composition includes the appropriate active agent listed below. Specific indications for active agents can be found in the Physicians’ Desk Reference (58% Ed., 2004, Medical Economics Company, Inc., Montvale, NJ), which is herein incorporated by reference. The active agents in the table below include their analogs, fragments, mimetics, and polyethylene glycol-modified derivatives. :
Active Agent Non-Limiting Examples of Disease And
Physiological Effect
High Cholesterol (To Lower Cholesterol)
Antimicrobials, including Antibiotics, Infection Including Gram-Positive
Anti-Bacterials and Anti-Fungal Agents; Bacterial Infection non-limiting examples of Antibiotics include Gram-Positive Acting,
Bacteriocidal, Lipopeptidal and Cyclic
Peptidal Antibiotics, such as Daptomycin
And Analogs thereof;
Anti-Migraine Agents such as BIBM- Migraines 4096BS And Other Calcitonin Gene-
Related Proteins Antagonists, Sumatriptan
Succinate;
Antivirals including Acyclovir, Viral Infections
Valacyclovir;
Bisphosphonates, including Alendronate, | Cancer, Atherosclerosis, Osteoporosis And
Clodronate, Etidronate, Ibandronate, Paget's Disease; Inhibits Osteoclasts
Incadronate, Minodronate, Neridronate,
Olpadronate, Pamidronate, Risedronate,
Tiludronate, Zoledronate, EB1053, and
YHS529;
Calcitonin, including Salmon, Eel, Porcine Osteoporosis; Diseases Of The Bone
And Human; . :
Cholecystokinin (CCK) And CCK Obesity
Agonists Including CCK-8;
Cromolyn Sodium (Sodium Or Disodium Asthma; Allergies
Chromoglycate);
Cyclosporine; Transplant Rejection :
Desferrioxamine (DFO); Iron Overload
Exedin and Exedin Agonists, including Diabetes; Obesity :
Exendin-3, Exendin-4;
Filgrastim Reduce Infection In Chemotherapy
Patients
Follicle Stimulating Hormone Regulate Reproductive Function (recombinant and natural);
Glucagon-Like Peptide 1 (GLP-1), Diabetes; Obesity
Glucagon, and Glucagon-Like Peptide 2 (GLP-2); :
Glucocerebrosidase; Gaucher Disease (To Metabolize
Lipoprotein)
Gonadotropin Releasing Hormone; Ovulatory Disfunction (To Stimulate
Ovulation)
Growth Hormone Releasing Factor; Growth Disorders
Growth Hormone Releasing Hormones; Growth Disorders
Growth Hormones, Including Human Growth Disorders :
Growth Hormones (hGH), Recombinant
Human Growth Hormones (thGH), Bovine
Growth Hormones, And Porcine Growth
Hormones;
Heparin, Including Unfractionated Thrombosis; Prevention Of Blood
Heparin, Heparinoids, Dermatans, Coagulation
Chondroitins, Low Molecular Weight
Heparin, Very Low Molecular Weight
Heparin Ultra Low Molecular Weight
Heparin and synthetic heparins including
Fondiparinux;
Immunoglobulin Infectious disease, and blood dysplasias,
Insulin, Including Porcine, Bovine, Diabetes; Insulin Resistance Syndrome
Human, And Human Recombinant,
Optionally Having Counter Ions Including :
Zinc, Sodium, Calcium And Ammonium;
Insulin-Like Growth Factor, Including Diabetes
IGF-1;
Interferons, Including o (E.G., Interferon | Viral Infection, Including Chronic Cancer
Alfacon-1 (Available As Infergen® From And Multiple Sclerosis
Intermune, Inc. Of Brisbane, Ca)), alpha, B, : omega and vy;
Interleukin-1; Interleukin-2; Interleukin- Viral Infection; Cancer 11; Interleukin-21;
Leutinizing Hormone and Leutinizing Regulate Reproductive Function
Hormone Releasing Hormone;
Monoclonal Antibodies including Retuxin, To Prevent Graft Rejection; Cancer
TNF-alpha soluble receptors;
Oxytocin; Labor Dysfunction (To Stimulate
Contractions)
Parathyroid Hormone (PTH), Including Its Osteoporosis; Diseases Of The Bone
Fragments, including PTH 1-34 and PTH 1-38;
Peptide YY (PYY) Including PYY Obesity; Diabetes; Eating Disorders;
Agonists, Fragment 3-36; Insulin Resistance Syndrome
»
Vaccines Including Those Against Anthrax Prevent And Minimize Disease
Or Y. Pestis, Influenza, and Herpes;
[121] The following examples illustrate the present invention without limitation.
All percentages are by weight unless otherwise specified.
Example 1 "Preparation of Heparin/SNAC Capsules
[122] The SNAC/heparin formulation in Table 1 below was prepared as follows.
Table 1
Component Target Amount Acceptable Range (mg/capsule) (mg/capsule)
SNAC 229.59 218.0 -241.1
Heparin sodium, USP 107.14 101.14 - 112.5 (15,000 USP
Heparin Units)
Polyethylene Glycol 226.13 214.8 -237.4 (PEG) 300
Sodium Lauryl 6.70 64-70
Sulphate .
Propylene glycol 100.44 95.4-105.5 monocaprylate (Capmul® PGS)
Total weight 670.0 635.7 —703.5
[123] Propylene glycol monocaprylate is available as Capmul® PG8 from Abitec
Corporation of Columbus, Ohio.
[124] SNAC was milled using a Quadro Comil™ milling machine available from Quadro Engineering Inc. of Waterloo, Ontario, equipped with a 35-mesh screen equivalent.
The milled SNAC and heparin sodium, USP were passed through a 35 mesh screen. Sodium lauryl sulphate was added, and the mixture was blended using a 4-quart V-blender shell for 15 minutes. Polyethylene glycol 300 and propylene glycol monocaprylate were separately mixed in a stainless Kitchen Aid™ mixer for 15 minutes. The SNAC/heparin sodium USP/sodium lauryl sulphate blend was added in small increments to the PEG 300/propylene glycol monocaprylate mixture, and mixing was continued. Mixing was continued for 15 minutes after all of the milled
SNA C/heparin sodium USP/sodium lauryl sulphate blend was added.
[125] Size 0 Licap Capsugel hard gelatin capsules (available from Capsulgel of
Morris Plains, NJ) were manually filled with the resulting formulation.
Comparative Example 1
[126] 200 (+ 3) mg of microcrystalline cellulose were filled into size 0 Capsugel hard gelatin capsules and used as a placebo.
Comparative Example 2
Lyophilized Tinzaparin Tablets
[127] Tablets having the formulation shown in Table 2 were prepared as follows.
[128] SNAC was milled using a Quadro Comill equipped with a 35 mesh screen.
Tinzaparin was lyophilized using a VirTis Lyophilizer (available from VirTis of Gardiner, NY) as follows. The tinzaparin was dissolved in purified water to produce a solution with a concentration of about 100 mg/mL. The lyophilizer shelves were pre-cooled to -40° C. The tinzaparin solution was then transferred to 3 trays, each tray having about 1.6 kg of solution. The trays were transferred to the lyophilizer and lyophilized to obtain a dry powder. The dry powder was then assayed for tinzaparin content and used for tablet manufacture.
[129] The tablets were manufactured as follows. The required amounts of lyophilized tinzaparin sodium, USP, SNAC, dibasic calcium phosphate dehydrate, USP and sodium lauryl sulphate were weighed out and charged into a 16 Quart V-blender shell. The materials were blended for 15 minutes. The resulting blend was divided into 3 sublots for granulation. Each sublot was transferred into a SL bowl of a Key Instruments KGS high shear granulator (Key Instruments, Inc, of Englishtown, NJ) and granulated with water as the granulation fluid. After all three sublots were granulated, the wet granulations were transferred to trays and dried in a vacuum oven at 50° C at < 5.0 Hg (vacuum) until the moisture content was less than 15%. The dried granules were milled using a mill equipped with a 35 mesh screen.
The milled granulation was assayed for SNAC and tinzaparin content. ‘Based on the tinzaparin assay of the granulation, calculations for extragranular excipients were made.
[130] The extragranular excipients, dibasic calcium phosphate dehydrate, fumed silica and magnesium stearate, were sieved through a 35 mesh screen and the required amounts weighed out. The milled and dried SNAC/tinzaparin granulation was transferred to an 8 Quart
V-blender shell together with the dibasic calcium phosphate dehydrate and fumed silica and blended for 15 minutes. After blend uniformity testing, magnesium stearate was added and blended for 3 minutes. The resulting blend was compressed into tablets using an EK-O single station tablet press (Korsch AG, Berlin, Germany). The target tablet weight was 1100 mg with an acceptable range of 1067 — 1133 mg while the target tablet thickness was 15 kP with and acceptable range of 10 — 20 kP. . : Table 2
Component Amount (mg/capsule)
Lyophilized tinzaparin B 160.60* (15,000 USP Heparin Units)
Dibasic calcium phosphate dihydrate 293.01
Sodium lauryl sulphate 222.19 * . Based on a potency of 93.4 U/mg.
Comparative Example 3
Unlyophilized Heparin Tablets
[131] Tablets having the formulation shown in Table 3 were prepared by the procedure described in Comparative Example 2, except the heparin was not lyophilized.
!
Table 3 :
Component Amount . ~ (mg/capsule)
Unlyophilized heparin 170.26% (30,000 USP Heparin Units)
Dibasic calcium phosphate dihydrate 152.95
Comparative Example 4 }
Lyophilized Heparin Tablets
[132] Tablets having the formulation shown in Table 4 were prepared by the procedure described in Comparative Example 2. : Table 4
Component : Amount (mg/capsule)
Lyophilized heparin 170.26 (30,000 USP Heparin Units)
Dibasic calcium phosphate dihydrate 152.95
Example 2 -
Data from Formulations of Example 1 and Comparative Examples 1-4
[133] Fifteen human test subjects were administered each of the formulations described in Example 1 and Comparative Examples 1-4 in 6 periods, each separated by a 72-hour washout period. For every period, subjects entered a clinic the evening before the administration to begin an 8-hour fast starting at 10 p.m. The formulation was administered in the moming in a fasted state. Table 5 summarizes the six periods and the formulations administered.
Table 5
Period Formulation Number of Unit Total Amount of | Total Amount
Dosages Heparin of SNAC (Tablets, Capsules) | (or tinzaparin) (U) (mg) 1 Comparative
Example 1
Example 60,000 3 Comparative 3 45,000 2079
Example 2
Bemplel | 6 | 900m 1380
Comparative 2 60,000 920
Example 3
Comparative 2 60,000 920
Example 4 (n=13) : [134] For each period, the anti-Factor Xa and anti-Factor Ila activities were measured from blood samples taken at 15 and 5 minutes before dose, and 5, 15, 30, 45, 60, 90, and 120 minutes after dose. Anti-Factor Xa and anti-Factor Ila activities and aPTT times are indicators of heparin response, and provide a basis to compare the bio-availability of the respective formulations.
[135] The results for the 15 subjects were averaged for each sample period, and are shown in the tables below. : on Table 6
Anti-Factor Xa Activity (IU/ml) (Standard Deviation shown in parenthesis)
Ton cn I YN AC NT I -15 003 007 0.039 on .006 0 (0.0046) (0.0110) (0.024) (0.014) (0.012) ©) -5 .002 .005 .024 .003 .002 .002 (0.0077) (0.0136) (0.021) (0.008) (0.006) (0.008)
S 0 012 .042 .053 026 .012 ()) (0.0224) (0.046) (0.055) (0.029) (0.019) 004 .051 .081 268 055 .036 (0.0155) (0.0685) (0.061) (0.166) (0.051) (0.048) 30 .001 153 .129 355 .051 .025 (0.0026) (0.0930) (0.054) (0.189) (0.053) (0.050) 45 0 173 145 313 .039 .023 (1) (0.1449) (0.052) (0.190) (0.042) (0.044) 0 1.139 116 212 009 .005 (©) (0.1522) (0.059) (0.151) | (0.019) (0.019) 0 075 .083 137 002 0 (©) (0.1041) (0.044) (0.132) (0.006) 0) 120 .001 .041 061 .018 .003 .002 (0.0026) (0.0508) (0.033) (0.022) (0.007) (0.006)
Table 7
Plasma anti-Factor Xa Pharmacodynamic Parameters
Period Emax, TEmax, hr | EAUC (0- EAUC (0- EMRT, hr
IU/ml (CV, %) last) inf) (CV, %) (CV, %)" (CV, %) (CV, %) 0.01 0.432 (160.30) (174) 2 0.20 0.719 0.2082 0.3935 1.24 (69.42) (54.0) (80.39) (62.31) (28.1) 3 0.16 0.723 0.1941 0.3241 1.42 (33.41) (28.3) (39.77) (28.01) (13.4) 4 0.36 0.707 0.4171 0.4528 1.25 (50.83) (20.1) (58.08) (43.43) (19.2) 0.07 0.516 0.06632 0.1528 1.14 (70.74) (35.9) (55.74) (45.58) (45.3) 0.05 0.513 0.06261 (93.81). (48.5) (81.38)
Table 8
Anti-Factor [1a Activity (IU/ml) wim) [15 Ta | a [5] -15 .089 025 039 035 024 015 (0.254) (0.029) (0.027) (0.024) (0.024) (0.017) -5 .026 025 .062 .045 .028 .023 (0.030) (0.028) (0.012) (0.019) (0.019) (0.018) 5 034 -.029 .058 .074 .039 027 (0.036) (0.029) (0.013) (0.039) (0.020) (0.020) i5 .030 .058 067 304 073 041 (0.033) (0.057) (0.016) (0.135) (0.031) (0.025) 30 .033 137 .079 383 074 038 (0.034) (0.069) (0.025) (0.243) (0.035) (0.033)
45 .032 .160 .088 382 055 .035 (0.033) (0.092) (0.037) (0.248) (0.032) (0.033) .027 .140 071 248 042 021 (0.031) (0.090) (0.036) 0.211) (0.018) (0.030) .024 107 .083 165 048 .018 (0.026) - (0.061) (0.026) (0.153) (0.029) (0.018) 120 .024 .069 077" .044 .039 .009 (0.031) (0.040) (0.016) (0.024) 0.021) (0.013)
Table 9
Plasma anti-Factor Ila Pharmacodynamic Parameters
Period Emax, TEmax, hr | EAUC (0- EAUC (0- | EMRT, hr
IU/ml (CV, %) last) inf) (CV, %) (CV, %) (CV, %) (CV, %) 1 0.05 0.511 0.06896 (66.44) (119) (80.44) 2 0.18 0.706 0.2148 0.1702 1.00 (50.08). 27.1) (49.14) (16.44) (15.5) 3 0.11 1.02 0.1543 (24.65) (48.9) (22.40) 4 0.42 0.773 0.5028 0.4131 1.18 (56.68) (29.1) (63.54) (34.23) (12.1) 0.09 0.831 0.1011 (35.40) (79.8) (33.74) 0.06 0.612 0.06181 (42.54) (44.0) (60.62)
Table 10
Ratio of Anti-Factor Xa Activity to Anti-Factor IIa Activity wim) TT Ta [a [5 |e [ae [ow | ww | ow | om | aw [om | ow | ow | oo | ow | ow
Ts ow [on [en | om | oe | ew aw [ww | te | ie | om | oe | os sow [iw | we | om | on | oo a ow | ow | ie | os | oan | va wow | on | wo | om | ow | oo
Tw | om | ow | wm | om | oo | oz
Table 11
Plasma SNAC Concentrations (ng/ml.) (Standard Deviation shown in parenthesis) mime) TT Ta [a [5 |e]
NA 0 2.36 0 0 0 (0) (9.15) (0) © ©)
NA 100.44 1394.87 60.19 812.04 512.09 (276.47) (1630.58) 67.57) (648.93) (322.79)
NA 4731.95 10139.4 4168.13 3612.24 4339.32 (3900.82) | (5481.83) (2515.09) (2286.80) | (2010.81)
NA 4432.24 8846.83 5973.36 2995.23 3269.97 (2404.94) | (4170.31) (2913.61) (1184.70) | (1352.39) 45 NA 1747.60 4853.39 4114.45 1399.63 871.15 (1062.02) | (3245.89) (2359.29) (762.69) (274.51)
NA 693.87 2095.89 1637.34 682.07 513.43 (352.40) (1205.31) (902.59) (282.92) (160.84)
NA 535.45 1313.09 833.55 416.42 427.28 (290.47) (571.42) (400.36) (218.59) (210.71) 120 NA 373.32 1247.41 726.43 373.02 344.04 (273.87) (861.34) (529.29) (305.72) (432.82)
Table 12
Plasma SNAC Pharmacokinetic Parameters
Period Cmax, Tmax, hr | AUC (0- | AUC (0- Tip, hr CL/F, Vd/F,L ng/ml (CV, %) last), inf), (CV, %) L/hr (CV, %) (CV, %) . ng*hr/ml | ng*hr/ml (CV, %) (CV, %) | (CV, %) 2 5907.10 0.436 3189.9 3194.0 0.522 301.62 229.13 (57.65) (39.9) (35.630) (24.783) (54.6) | (21.497) | (61.386) 3 11,874.21 0.392 7611.9 9141.8 0.618 239.91 215.66 : (41.13) 42.4) (33.044) (26.432) (54.9) | (24.467) | (64.28) 4 6,969.23 0.572 4632.7 4783.7 0.444 291.26 188.31 (39.77) (26.1) (22.895) (10.429) (39.6) | (11.009) | (43.187) 4456.64 0.348 2580.5 2833.4 0.454 339.51 226.25 (41.28) 42.9) (30.130) |" (25.429) (38.7) | (20.392) | (45.799) 4637.60 0.331 2685.5 3016.5 0.730 317.07 326.35 (40.53) (38.0) (26.388) (20.316) (45.2) | (21.644) | (44.825)
Table 13
Plasma aPTT (seconds) (Standard Deviation shown in parenthesis)
Tin ime |v [72 J 0s [4 | 5s | 6 26 26 26 26 26 26 2) (2 2) @ 2 2 26 © 27 2) 2 : 30 26 35 31 47 29 29 (2) (6) 4) (15) 3 (3) 45 27 38 31 49 28 28
NE) (11) 4) (20) €)) €)] © 32 30 48 27 27 4) (6) (3) (23) 2 2 120 25 28 28 34 26 27 2 2 @ (13) @ 2 480 26 26 26 26 26 26 2 2) (2) @) (2) 2
Table 14
Plasma aPTT Pharmacokinetic Parameters
Period | Emax, sec TEmax, hr EAUC (0-last) (CV, %) (CV, %) sec*hr oo (CV, %) 1 27. 0.305 52.795 (1D (127) (9.5374) 2 38 0.604 64.372 (28) (25.6) (17.531) : 3 32 0.583 58.736 (13) (17.3) (9.5973) 4 54 0.771 82.333 41) (49.8) (32.203) 29 0.408 54.809 $3) (63.0) (7.924) : 29 0.469 67.017 (12) (48.6) (12.861)
[136] As shown in Tables 6 and 8 and Figures 1 and 2, the wetted heparin formulations generally showed higher anti-Factor Xa and IIa activities (Periods 2 and 4) than the placebo (Period 1) and non-wetted heparin/SNAC tablets (Periods 3, 5, and 6). As shown in
Table 13, the wetted heparin formulations generally showed increased Plasma aPTT times than the placebo and non-wetted heparin/SNAC tablets.
Example 3
[137] Soft gelatin capsules having the formulations shown in Tables 15a, 15b, and 15c were prepared as described below.
Table 15a (3% by weight)
Table 15b : weight (mg)
Table 15c¢
Component mg/capsule | % of Capsule | Acceptable range
Weight (mg)
SNAC 250.00 21.37 142.5 -257.5
Heparin Sodium, USP (37,500 Units) £267.86 <22.89 <259.8-275.9
Polyethylene Glycol 300, NF (PEG 300) 405.00 34.62 3929-4172
Capmul® PGS 164.00 14.02 159.1 — 168.9
Purified Water, USP 81.99 79.5 — 84.4
Soybean Oil, USP (Super Refined) >1.12-1.18 :
Total weight 1170.00 100.00 1134.9 -1205.1
Preparation of Gel Mass
[138] The gel mass for the capsules had the formulation shown in Table 16 below and was prepared as follows. A gel holding tank was pre-heated to 55 °C. The hot water jacket heater of the gel melter was turned on and the temperature controller set to 90 °C. The required amount of purified water, USP was weighed out and charged into the gel melter and the mixer turned on. Approximately 3 kg of the required purified water, USP was reserved in a separate container for color transfer. The required amount of the glycerin, 99.7%, USP was charged into the gel melter followed by scraping of the container to assure complete transfer.
The required amount of anhydrized liquid sorbitol, USP was charged into the gel melter and the container scrapped to ensure complete transfer. The access door and all release valves on the dome of the gel melter were then closed and left to heat until the temperature was greater or equal to 80 °C. The gel melter access door and release valves were opened and the required amount of gelatin, NF charged into the gel melter and turn off the mixer after addition is completed. The access door and pressure valves were closed, the mixer turned on and the hot water jacket heater controller set-to 85 °C. Mixing and heating was continued for 75 + 10 minutes after the temperature had reached at least 80 °C. The gel mass was inspected (if there is no visual evidence of un-dissolved particles the gel mass is done). The vacuum pump water hose was connected to the water outlet and the cold water and vacuum pump turned on. The gel mass was deaerated and the mixer and vacuum pump turned off after the gel mass had no visual’ evidence of air bubbles. ’
[139] The White Opatint G-18000 was mixed thoroughly in its original container with a stainless steel paddle and the required amount was weighed out. The FD&C
Green No. 3 and D&C Yellow No. 10 were weight out and dissolved in approximately one fourth (1/4th) of the reserve water.
[140] The access door of the gel melter was opened and the Opatint and the dye mixture were slowly added with the mixer on. The release valves and the access door were then closed and the vacuum pump turned on. The colorized gel mass was deaerated for 10+ 5 minutes followed by release of all valves and turning off the mixer and vacuum pump. Samples were taken for viscosity and water content determination. The water content of the gel mass was adjusted to approximately 26% by adding water if it was less than 26% or further heating if it was above 26%. The gel mass was transferred to a pre-heated, pre-weighed gel holding tank and the temperature maintained at about 55 °C.
Table 16
Component Quantity % w/w Range (mg) required (kg)
Gelatin, NF (150 Bloom Limed Bone, Type B) 61.500 41.00 59.66 — 63.35
Glycerin, 99.7%, USP oo 21.000 14.00 20.37 - 21.63
Anhydrized Liquid Sorbitol, USP "13.500 13.10- 13.91 (Sorbitol Special, 76%) :
Purified Water, USP 50.964 33.98 49.44 - 52.49
White Opatint G-18000 3.000 2.91 -3.09
FD&C Green No. 3 0.021 0.014 0.02 -0.022
D&C Yellow No. 10 0.015 0.010 0.0146 - 0.0155
Total weight 149.996 145.50 — 154.50
Preparation of Heparin/SNAC Soft Gelatin Capsules
[141] The required amount of heparin sodium, USP was milled to a particle size not more than 180 um using a Quadro Comil® 197 equipped with a round impeller and a Comil
Screen 2A006R04227587 (80 Mesh). The required amounts of polyethylene glycol 300, NF (PEG 300) Capmut® PGS8, purified water, USP, and the soybean oil, USP were weighed out and transferred to an appropriately sized stainless steel container. An overhead stirrer was placed into the mixture and the container placed on a hot plate. Mixing and heating were than initiated.
Heating was continued until the mixture temperature reached 40 + 10 °C after which the mixture was blanketed with nitrogen.
[142] For the 250 mg/37,500 IU formulation, SNAC was charged into the mixture while stirring. Mixing was continued until the SNAC was well distributed. Heparin sodium, USP was charged into the mixture with continuous stirring. Mixing was continued until
' the heparin was well distributed. The mixer was then turned off and the mixer blades and shaft scraped to clean.
[143] For the 383 mg/25,000 formulation, the SNAC and milled heparin were blended in a bag for about 1 minute. The resulting blend was charged into the solvent system and mixing was continued until the heparin/SNAC blend was well distributed. The mixer was then turned off and the mixer blades and shaft scraped to clean.
[144] For either formulation the resulting suspension was removed from the hot plate and milled using a Vertical Colloid Mill with hopper. The aggregate size of the suspension before and after milling was determined using a using a fineness of grind gauge. Milling was continued until the aggregate size was less than 180 pm. The temperature of the suspension was measured after completion of milling. If necessary the suspension was reheated to a temperature between 30 — 50 °C. The suspension was then placed in to a vacuum chamber and deaerated until no bubbles were observed. In-process samples of Heparin/SNAC suspension were then collected. The heparin/SNAC suspension was covered and maintained at 30 — 50 °C with continuous slow mixing.
[145] The heparin/SNAC soft gelatin capsule formulation was encapsulated with the gel mass prepared as described above using a Bochang Encapsulator. 1% w/w soybean lecithin solution with Miglyol 812 (carylic/capric triglyceride) was used as a lubricant for the encapsulator machine. The heparin/SNAC suspension was charged into the hopper of the - encapsulator and continuously stirred. The equipment was set-up so that the target capsule fill weight was 1267 mg with an acceptable range of 1204 to 1330 mg, the trailing edge seam thickness acceptable limit was at least 0.25 mm and the ribbon thickness had a target of 0.81 = 0.05 mm. After encapsulation, the capsules were dried until the gel shell moisture content was less or equal to 8% and the water content of the fill material (heparin/SNAC suspension) was less or equal to 9%. After drying samples were sent for release testing. The capsules were then packaged in a 100 cc white HDPE wide mouth bottle with 38 mm Child Resistant, foil lined, suitable for induction sealing caps and low moisture cotton coil. Thirty (30) capsules were filled per bottle. : '
Example 4 :
[146] Hard gelatin capsules containing 15,000 IU heparin, 250 mg SNAC, 15% (w/w) Capmul® PG8 (propylene slycol monocaprylate) or Capmul® MCM (glyceryl caprylate/caprate) (available from Abitec Corp. of Columbus, OH), 37% PEG 300, and 1% sodium lauryl sulphate were prepared as described below. Hard gelatin capsules were also prepared with the aforementioned formulation without SNAC or with 2% Carbopol® 934P (available from Noveon of Cloveland, OH).
[147] First, the liquid excipients (e.g., Capmul® PG-8 or Capmul® MCM and
PEG-300) were mixed in a mortar to obtain a homogeneous liquid mixture. To this mixture, various solid components were slowly incorporated in proportions until a homogeneous mixture of paste (or suspension) consistency was obtained. These solid materials included SNAC, heparin, sodium lauryl! sulphate, and optionally Carbopol® 934P. Once the homogeneity of the paste (or suspension) was ensured, the mixture was manually filled into into appropriate size hard gelatin capsules. The filled capsules were sealed at the joint between the body and cap by wetting the rim of the body with 50:50 (% v/v) mixture of ethyl alcohol and purified water. The capsules were stored frozen at -20°C until used.
[148] Soft gelatin capsules having the formulations shown in Table 15a, prepared as described in Example 3, were administered to 4 male Rhesus monkeys as follows.
Rhesus monkeys weighing between 3.5 - 5.0 kg were fasted overnight before the experiments and food was returned about 2 hours after dosing of the solid. Water was withheld from 30 minutes prior to dosing until 30 minutes after dosing, except for those quantities used for dosing.
Each dosage form was delivered to the rear of the mouth using a pill gun. After release of the dosage form, 5 ml of reverse osmosis water was administered into the oral cavity to facilitate swallowing. Following delivery, the oral cavity was inspected to ensure that the solid was swallowed.
[149] Hard gelatin capsules having the formulation shown in Table 1 and prepared as described in Example 1 were administered to 7 male Rhesus monkeys as described above.
[150] Antifactor Xa from blood samples was measured over 400 minutes. The results for each group was averaged, and are shown in Figure 3.
Example 6 [1511 Hard gelatin capsules having the formulation described in Example 4 (15,000 IU heparin, 250 mg of SNAC, 15% (Ww) Capmul® PG8, 37 % PEG 300, and 1% sodium lauryl sulphate) with and without 2% Carbopol® 934P were prepared. Hard gelatin capsules having the formulation described in Example 4, but without the SNAC were also prepared.
[152] The capsules containing SNAC and heparin with or without Carbopol were administered to 8 Cynos monkeys by the following procedure. Cynomolgus monkeys were fasted at least 24 hours prior to dosing. One capsule was inserted at the tip of a tubing, and air flushed to discharge the capsule into the stomach. Food was returned 2 hours after dosing.
Water was available at all times. Approximately 1.3 ml of whole blood was collected into citrated tubes at pre-dose, and over 400 minutes post dosing. Antifactor Xa from the blood samples was measured.
[153] The capsules without SNAC were administered to 4 Cynos monkeys as described above.
[154] The results for each of the three groups were averaged, and are shown in
Figure 4.
Example 7
[155] Hard gelatin capsules having the formulation shown in Table 17, and prepared as described in Example 1 were prepared. The capsules were administered to a group of 8 Rhesus monkeys (1 capsule/monkey) by the procedure described in Example 5.
Table 17
SNAC 250.0 mg
Heparin sodium, USP 15,000 TU
Polyethylene Glycol (PEG) 300
Sodium Lauryl Sulphate
Capmul PG8 (Propylene glycol 15 wt% monocaprylate)
[156] Antifactor Xa was measured from blood samples over 6 hours. The results were averaged, and are shown in Figure 5. :
Example 8 ] [157] Hard gelatin capsules having the formulation shown in Table 18 were prepared as described in Example 1. The capsules were administered to a group of 8 Rhesus monkeys.
Table 18
SNAC : 250.0
Heparin sodium, USP 14,930 IU
Polyethylene Glycol (PEG) 300
Sodium Lauryl Sulphate
Capmul® MCM (mono and di-glycerides of 15% medium chain fatty acids (mainly caprylic and capric))
[158] Capmul® MCM is available from Abitec Corporation of Columbus, Ohio.
This formulation is identical to that of Example 7 except Capmul® MCM is substituted for
Capmul® PGS.
[159] Antifactor Xa was measured from blood samples over 6 hours. The results were averaged, and are shown in Figure 6.
[160] The results of from Examples 7 and 8 (Figures 5 and 6) are overlayed in
Figure 7. :
Example 9
[161] Hard gelatin capsule having the formulation shown in Table 1 and prepared as described in Example 1 was administered to 4 Rhesus monkeys (1 capsule/monkey) by the procedure described in Example 5. Antifactor Xa was measured over a period of about 400 minutes after administration.
[162] The results were averaged and are shown in Figure 8.
Example 10
[163] Hard gelatin capsules having the formulation shown in Table and prepared as described in Example 1 were administered to a group of 4 Rhesus monkeys (1 capsule/monkey) by the procedure described in Example 5.
[164] Antifactor Xa activities and aPTT were measured over 400 minutes. The results were averaged and are shown in Figure 9.
Example 11
[165] Hard gelatin capsules having the formulation shown in Table 19 were prepared as described in Example 1. The capsules were administered to 4 Rhesus monkeys (1 capsule/monkey) by the procedure described in Example 5.
Table 19 (mg/capsule) (Capmul® PGS)
[166] The formulation of Table 19 is identical to the formulation of Table 1 except sodium lauryl sulfate is excluded. Antifactor Xa activities and APTT were measured over 400 minutes. The results were averaged and are shown in Figure 10. ) Example 12
[167] Hard gelatin capsules having the formulation of Example 1, but with varying amounts of SNAC such that the ratio of SNAC:Heparin was 0.5:1, to 1:1, 2:1,and 2.5:1. (In Example 1, the SNAC:heparin ratio was about 2.5:1). The capsules were administered to
Rhesus monkeys (1 capsule/monkey) by the procedure described in Example 5. The formulations containing 0.5:1, 1:1, 2:1, 2.5:1 of SNAC:heparin were administered to 4, 4, 4, and 7 monkeys, respectively.
[168] Antifactor Xa activities were measured from blood samples over a period of about 400 minutes. The averages for the four groups are shown in Figure 11.
Example 13
[169] Stability tests were conducted on the hard gelatin capsules described in
Example 1. The capsules were administered to Rhesus monkeys by the procedure described in
Example 5. The capsules were stored for 15 days at 40 °C and 75% relative humidity or 25 °C and 60% relative humidity. The capuies were then administered to two groups of Rhesus monkeys. Antifactor Xa activities and aPTT were measured over about 400 minutes for each administration.
[170] These results were averaged and are shown in Figures 12 and 13.
[171] Figure 14 compares the Average Antifactor Xa activities for the semi-solid capsules described in Example 1 and administered the day it was formulated (t=0) and after 15 days (t=15 days) at 25 °C/ 60% RH. Figure 15 compares the Average Antifactor Xa activity for the semi-solid capsule described in Example 1 and administered the day it was formulated (t=0) and after 15 days (t=15 days) at 25 °C/ 75% RH. The capsules were administered to Rhesus monkeys by the procedure described in Example S.
Comparative Example 5
Preparation of Tablets (Without Heparin)
[172] Tablets having the formulation described in Table 20 were prepared as described below.
Table 20 (Target) weight (acceptable range)
Propylene Glycol, USP/EP/JP 38.80 -41.2
Capmul® PGS 10.00 77.6 — 82.40
Dibasic Calcium Phosphate, >268.75 >33.59
Anhydrous, USP/EP (Anhydrous
Emcompress)
Colloidal Silicon Dioxide, 16.00 2.00 15.52 16.48
USP/NF/EP (Aerosil® 200 VV :
Pharma)
Povidone K90, USP/EP/JP 4.25 0.53 4.12 -4.37 (Kollidon 90F)
Magnesium Stearate, NE/EPAP ~~ | 800 | 100 | 776-824
Total weight 800.00 100.00 776 — 824.00
[173] The SNAC and a portion of the intragranular Emcompress™ (available from JRS Pharma, Patterson, NY) were weighed out, transferred to a 16 quart stainless steel V- blender shell and blended for 15 minutes. The resulting blend was then divided into four sub- lots for granulation. For the granulation of each sub-lot the SNAC blend was transferred to a SL bowl of a Key Instruments KG-5 high shear granulator (available from Key Instruments,
Trevose, PA). Granulation was first performed using a mixture of the required amount of
Capmul® PG8 and propylene glycol as the granulation fluid followed by the required amount of
Povidone K90 solution (available from BASF, Ludwigshafen, Germany) in water as the granulation fluid. The granulation was completed with purified water as the final granulation fluid. The resulting granulation was transferred to a polyethylene lined container for in-process storage. The other three sub-lots were also granulated and stored in a similar fashion. The granulations were transferred to stainless steel trays and dried in a vacuum oven at about 40 °C for at least 4 hours. The dried granules were transferred into a polyethylene bag and blended for not less than one minute. The blended granules were milled using a Vector Granul Mill Jr. mill (available from Vector Corp., Marion, [A) equipped with a 35 mesh screen. The moisture content of the milled granules was determined using a Karl- Fisher Coulometer. The granules were considered dry if the moisture content was not more than 10% w/w. If the moisture content was more than 10% w/w, drying was continued until an acceptable moisture content was obtained. The moisture content of the granulation was used for calculations to adjust the - quantity of extragranular anhydrous Emcompress™'to be added to the granulation. The dried granules were transferred to a polyethylene lined container for in-process storage.
[174] The required amount of Aerosil® 200 VV Pharma (available from Degussa
AG, Wolfgang, Germany) was sieved through through a 35 mesh screen. The remaining portion of amount of anhydrous Emcompress™ was also weighed. The dried granules were then transferred to a 16 Quart stainless steel V-blender shell. The Aerosil® 200 VV Pharma and the anhydrous Emcompress™ were transferred to the same V-Blender shell. The shell was mounted - on to the Yoke of a Patterson-Kelly V-blender drive unit (available from Patterson-Kelly Co.,
East Stroudsburg, PA) and blended for 15 minutes. After successful blend uniformity testing, the required amount of magnesium stearate was weighed out, screened through a 35 mesh screen and transferred to the V-blender shell. The material was blended for 3 minutes. The resulting blend was compressed into tablets using a Korsch EK~O (available from Mori Machinery Co.,
Okayama, Japan) single station tablet press equipped with 16.5 mm by 7.5 mm oval shaped tooling. During compression, the following in-process tests were performed, friability, tablet hardness, tablet weight, tablet thickness and disintegration. The target tablet weight was 800 mg with an acceptable range of 776 - 824 mg and the target tablet hardness was 8 Kp with an acceptable range of 5— 11 KP. After release testing, the tablets were packaged in 30 count
HDPE bottles with pharmaceutics coil, child resistant cap and induction seal liner.
Comparative Example 6
Preparation of Heparin/SNAC tablets (25.000/383)
[175] Heparin/SNAC tablets having the formulation described in Table 21 were prepared as described below. :
Table 21
Component : mg/Tablet | % of Tablet mg/Tablet (Target) weight (acceptable range)
SNAC 383.00 47.88 371.51 -394.49
Heparin Sodium, USP <178.57 <22.32 173.21-183.93 (25,000 Units)
Propylene Glycol, USP/EP/JP 40.00 38.80 — 41.2
Capmul® PG8 80.00 | 1000 | 77.6 — 82.40
Dibasic Calcium Phosphate, >90.18 >11.27 87.47 —-92.89
Anhydrous, USP/EP (Anhydrous
Emcompress™)
Colloidal Silicon Dioxide, 16.00 2.00 15.52 -16.48
USP/NF/EP (Aerosil® 200 VV
Pharma)
Povidone K90, USP/EP/JP (Kollidon 4.25 0.53 4.12 -4.37 90F) :
Magnesium Stearate, NF/EP/JP 7.76 - 8.24
Total weight 800.00 100.00 776 — 824.00
[176] The required amount of heparin sodium, USP and milled SNAC were weighed out, transferred to a 16 quart stainless steel V-blender shell and blended for 15 minutes.
The resulting blend was divided into four sub-lots for granulation. For the granulation of each sub-lot the heparin/SNAC blend was transferred to a SL bowl of a Key Instruments KG-5 high shear granulator. Granulation was first performed using a mixture of the required amount of
"7 WO 2005107773 PCT/US2005/016012
Capmul® PG8 and propylene glycol as the granulation fluid followed by the required amount of
Povidone K90 solution in water as the granulation fluid. The granulation was completed with purified water, USP as the final granulation fluid. The resulting granulation was transferred to a polyethylene lined container for in-process storage. The other three sub-lots were also granulated and stored in a similar fashion. The granulations were then transferred to stainless steel trays and dried in a vacuum oven at about 40 °C for at least 4 hours. The dried granules were transferred into a polyethylene bag and blended for not less than one minute. The blended granules were milled using a Vector Granul Mill Jr. mill equipped with a 35 mesh screen. The moisture content of the milled granules was determined using a Karl-Fisher Coulometer. The granules were considered dry if the moisture content was not more than 10% w/w. If the moisture content was more than 10% w/w drying was continued. Samples were drawn for assay of SNAC and heparin in the dry granulation. The heparin assay (as is) was used for calculations to adjust the quantity of extragranular anhydrous Emcompress™ to be added to the granulation.
The dried granules were transferred to a polyethylene lined container for in-process storage.
[177] The required amount of Aerosil® 200 VV Pharma was sieved through a 35 mesh screen. The required amount of anhydrous Emcompress™ was also weighed. The dried granules were transferred to a 16 Quart stainless steel V-blender shell. The Aerosil® 200 VV
Pharma and the Anhydrous Emcompress were transferred to the same V-Blender shell. The shell was mounted on to the Yoke of a Patterson-Kelly V-Blender drive unit and blended for 15 minutes. Samples for blend uniformity testing were withdrawn. After successful blend uniformity testing the granulation the required amount of magnesium stearate was weighed out, screened through a 35 mesh screen and transferred to the V-blender shell. The material was blended for 3 minutes and compressed in to tablets using a Korsch EK-O single station tablet - 68 -
AMENDED SHEET press equipped 16.5 mm by 7.5 mm oval shaped tooling. During compression, the following in- process tests were performed, friability, tablet hardness, tablet weight, tablet thickness and disintegration. The target tablet weight was 780 mg with an acceptable range of 756.6 - 803.4 mg, the target tablet hardness was 8 Kp with an acceptable range of 5 - 11 KP. After release testing, the tablets were packaged in 30 count HDPE bottles with pharmaceutics coil, child resistant cap and induction seal liner.
Comparative Example 7
Preparation of Heparin/SNAC tablets (37,500/250)
[178] Heparin/SNAC tablets having the formulation described in Table 22 were prepared by the procedure described in Comparative Example 6. 69 -
AMENDED SHEET
Table 22
Component ) mg/Tablet % of Tablet mg/Tablet (Target) weight (w/w) | (acceptable range)
Heparin Sodium, USP . - <2679 <343 <259.8-275.9 (37,500 Units) .
Propylene Glycol, USP/EP/JP 37.8 -40.2
Capmul PG8 10.00 75.7- 80.3
Dibasic Calcium Phosphate, >117.8 > 15.1 >1143-121.3
Anhydrous, USP/EP (Anhydrous
Emcompress)
Colloidal Silicon Dioxide, 15.6 2.00 15.1 -16.1
USP/NF/EP (Aerosil® 200 VV
Pharma)
Povidone K90, USP/EP/IP 3.90 0.50 38-40 (Kollidon 90F)
Magnesium Stearate, NF/EP/JP | 78 | 10 | 7.6-8.0
Total weight 780.00 100.00 756.6 — 803.4
Comparative Example 8
Preparation of Liquid Heparin/SNAC
[179] 18 mL of the SNAC/heparin solution described in Example 1 of
International Publication No. WO 01/34114, which is hereby incorporated by reference, was prepared. The solution contained 90,000 [U of heparin and 2430 mg of SNAC.
Example 14
[180] Fifteen human test subjects were administered the formulations described in the chart below, each separated by a 72-hour washout period. For every period, subjects entered a clinic the evening before the administration to begin an 8-hour fast starting at 10 p.m.
The formulation was administered in the morning in a fasted state. Table 23 summarizes the periods and the formulations administered.
Table 23
Formulation Number of Unit Total Amount of | Total Amount
Dosages Heparin of SNAC (Tablets, Capsules) au) (mg)
A Comparative 3 1149
Example 5 ("SNAC control dose")
Example 3, 2 75,000 500
Table 15C ("capsule 1:1 ratio")
C Comparative 3 75,000 1149
Example 6 (“tablet 1:2.5 ratio")
Comparative 2 75,000 500
Example 7 ("tablet 1:1 ratio")
E Example 3, 3 75,000 1149
Table 15B (capsule 1:2.5 ratio)
F Comparative 18 ml (Liquid) 90,000 2430
Example 8 ("liquid reference dose")
[181] For each period, the anti-Factor Xa and Ila activities and aPTT times were measured from blood samples taken at 10 minutes before dosing, upon dosing, and 15, 30, 45, 60, 90, 120, and 480 minutes after dosing. Anti-Factor Xa and Ila activities and aPTT times are indicators of heparin response, and provide a basis to compare the bio-availability of the respective formulations.
[182] APTT and Anti-Factor Ila and Xa results for the 15 subjects were averaged for each sample period, and are shown below.
Table 24
Plasma aPTT (seconds) (Standard Deviation shown in parenthesis) me a Ts [ec [ » | ® | Ff -10 29.7 29.4 30.1 30.0 29.8 29.2 3.0) 2.1 (B.4 2.9 2.5) 2.5) 29.1 "29.1 29.4 29.4 28.9 29.1 2.5) @.1D 2.5) 2.2) 2.0) 2.7 30.1 31.6 37.5 32.4 32.7 41.1 2.9) 2.9 6.7) 2.7) 6.9) (14.8) 29.5 75.1 51.6 37.1 89.1 52.1 (2.70) (54.8) (25.6) 8.4) (63.8) (42.8) 45 29.3 78.4 60.2 38.1 102.6 53.7 (2.6) (56.4) 48.1) (12.9) (72.1) 43.2) 29.6 73.0 51.7 35.9 97.0 51.7 2.4) (57.8) (32.6) (11.49) (72.7) (43.0) 29.4 50.8 41.5 32.8 79.7 44.2 2.4) 3L7) (18.8) (7.5) (66.8) (36.7) 120 29.7 39.5 34.0 30.4 60.9 36.3 (2.3) (16.1) 7.9) (2.6) (50.4) (19.0) 480 293 29.2 29.4 29.4 29.3 29.3 (2.6) 2.0) 2.5) 2.5) 2.3) 2.2)
[183] These results are shown in Figure 16.
Table 25 aPTT Pharmacodynamic Parameters
Treatment Emax, Tmax, hr | EAUC (0- | EAUC (0-
Arm IU/ml (Median last), U | inf), (IU * (Standard Range) * hr/ml) hr/mL)
Deviation) (Standard | - (Standard
Deviation) | Deviation)
A 1.51 0.75 2.634 2.634 (2.30) (0.25-8.00) (3.925) (3.925) 56.14 0.50 1 84.100 84.100 (57.39) (0.50-1.00) | (109.584) | (109.584)
C 31.76 0.75 42.865 42.865 (47.78) (0.50-1.00) | (66.157) (66.157) © 9.31 0.50 12.088 12.088 (11.70) (0.25-0.75) | (15.239) (15.239)
E - 80.30 0.75 184.236 184.236 (77.38) (0.25-1.50) | (240.894) | (240.894)
F 25.89 0.75 55.308 55.308 (42.59) (0.25-8.00) | (120.021) | (120.021)
Table 26 aPTT Pharmacodynamic Analysis (LS (LS Means) Interval : Means)
LAST) im ETE
[184] As shown in Table 24 and Figure 16, the longest aPTT occurred in the following descending order: soft gelatin capsule 1:2.5 ratio (T reatment Arm E), soft gelatin capsule 1:1 ratio (Treatment Arm B), tablet 1:2.5 ratio (Treatment Arm C), liquid SNAC/Heparin
IE dose (Treatment Arm F), tablet 1:1 ratio (Treatment Arm D), and the SNAC control dose (Treatment Arm A). The increase in aPTT was approximately 2.4 times higher with the soft gelatin capsule 1:2.5 ratio than with the 1:2.5 ratio tablet and approximately 3 times higher than with the liquid SNAC/heparin dose.
[185] Shown in Table 26, based on'a 90% confidence interval around the difference for aPTT results under a Least Squares Means Analysis, the formulation comparisons showing statistically significant differences for EAUC(0-last) were the soft gelatin capsule 1:2:5 ratio (Treatment Arm E) to SNAC control dose (Treatment Arm A), capsule 1:2.5 ratio (Treatment Arm E) to liquid reference dose (Treatment Arm F), capsule 1:2.5 ratio (Treatment
Arm E) to capsule 1:1 ratio (Treatment Arm B), capsule 1:2.5 ratio (Treatment Arm E) to tablet 1:2.5 ratio (Treatment Arm C) and capsule 1:1 ratio (Treatment Arm B) to tablet 1:1 ratio (Treatment Arm D). The formulation comparisons showing statistically significant differences for Emax were as follows: capsule and tablet 1:2.5 ratios (Treatment Arms E and C) to SNAC control dose (Treatment Arm A), capsule 1:2.5 ratio and 1:1 ratios (E and B) to liquid reference dose (Treatment Arm F), capsule 1:2.5 ratio (E) to capsule 1:1 ratio (Treatment Arm B), capsule 1 :2.5 ratio (E) to tablet 1:2.5 ratio (Treatment Arm C), capsule 1:1 ratio (Treatment Arm B) to tablet 1:1 ratio (Treatment Arm D), and tablet 1:2.5 ratio (Treatment Arm C) to tablet 1:1 ratio (Treatment Arm D).
Table 27
Anti-Factor Ila Plasma Concentrations (TU/m[.) (Standard Deviation shown in parenthesis) me a Ts Te Tn [8 TF 0 [meme me | ome | ome me
BLQ 0.07 0.12 0.08 0.07 0.11 (0.05) (0.04) (0.05) (0.06) (0.08)
BLQ 0.30 0.20 © 0.12 0.33 0.15 (0.20) 0.11) (0.08) (0.23) (0.16) 45 BLQ 0.33 0.21 0.12 0.40 0.16 (0.22) (0.13) (0.10) (0.33) 0.17)
BLQ 0.29 0.20 0.10 0.39 0.15 0.21) 0.13) (0.11) (0.34) (0.18)
BLQ 0.20 0.14 BLQ 0.31 0.11 (0.16) (0.10) (0.31) (0.15) 120 BLQ 0.14 0.10 BLQ 0.23 0.08 (0.13) 0.07) (0.24) (0.11)
Mean values below 0.05 TU/ml, are denoted as below the limit of quantification (BLQ). For statistical purposes, individual values below the limit of quantification. (BLQ) were set to 0.025
IU/ml.
[186] The above results over 120 minutes are shown in Figure 17.
Table 28
Plasma anti-Factor Ila Pharmacodynamic Parameters
Treatment | Emax, IU/ml Tmax, hr EAUC (0- EAUC (0-inf),
Arm (Standard (Median last), (JU * (IU * hr/mL)
Deviation) Range) hr/mL) (Standard (Standard Deviation)
Deviation)
A 0.04 0.50 0.262 0.324 (0.04) (0.25-8.00) (0.261) (0.236) 0.36 0.75 0.714 0.905 022° (0.50-1.00) (0.771) (0.786)
C 0.22 0.75 0.566 0.715 0.13 (0.50-1.00) (0.391) (0.411) 0.13 0.50 0.369 0.418 0.10 (0.25-1.00) (0.369) . (0.364)
E 0.42 0.75 1.116 1.511 0.34 (0.50-1.00) (1.167) (1.214)
F 0.16 0.50 0.349 0.545 0.18 (0.25-1.00) (0.301) (0.636)
Table 29
Anti-Factor [la Pharmacodynamic Analysis
Variable Comparision Test (LS Reference (LS | Difference 90% Confidence :
Means) Means) Interval
EAC(0- B-F 0.714 0.357 0.357 -0.029, 0.744 ry C-F 0.571 0.357 0.214 -0.180, 0.608 hr/mL) D-F © 0.363 0.357 0.006 -0.403. 0.414
E-F 1.112 0.357 0.755 0.353, 1.157
E-B 1.112 0.714 0.398 0.011, 0.784
C-A 0.571 0.124 0.337, 0.585 0.571 0.363 0208 -0.196, 0.613 B-D | o74 0.363 0.352 0.045, 0.748 1112 0.571 0.541 0.149, 0.933
Emax 0.357 0.163 0.194 0.104, 0.284 (IU/ml) 0.220 0.163 0.057 20.033, 0.146
D-F 0.163 -0.035 -0.125, 0.054
E-F 0.416 0.163 0.253 0.163, 0.342
E-B 0.416 0.357 0.059 0.031, 0.148
C-A 0.220 0.043 0.177 0.088, 0.267 0.220 0.128 0.092 0.002, 0.182 B-D | 03% 0.128 0229 | 0.140,0319 0.416 0.043 0373 0.284 , 0.463
[187] As shown in Table 27 and Figure 17, the highest mean concentrations of anti-factor Ila occurred in the following descending order: soft gelatin capsule 1:2.5 ratio (Treatment Arm E), soft gelatin capsule 1:1 ratio (Treatment Arm B), tablet 1:2.5 ratio (Treatment Arm C), liquid SNAC/Heparin dose (Treatment Arm F), tablet 1:1 ratio (Treatment
Arm D), and the SNAC control dose (Treatment Arm A). The increase in both anti-factor IIa and anti-factor Xa mean concentrations was approximately 2 times higher with the soft gelatin capsule 1.2.5 ratio than with the 1:2.5 tablet and approximately 2.5 times higher than with the liquid references dose.
[188] Shown in Table 29, based on'a 90% confidence interval around the difference for antifactor Ila resulis under a Least Squares Means Analysis, the formulation showing statistically significant differences for EAUC(0-1ast) were the capsule 1:2.5 ratio (Treatment Arm E) to the SNAC control dose (Treatment Arm A), the liquid reference dose (F and the tablet 1:2. ratio (Treatment Arm C). The formulation comparisons showing statistically significant differences for Emax were as follows: capsule and tablet 1:2.5 ratio (Treatment Arms
E and C) to SNAC control dose (Treatment Arm A), capsule 1:2.5 and 1:1 ratios (Treatment
Arms E and B) to liquid reference dose (Treatment arm F), capsule 1:2.5 ratio (Treatment Arm
E) to tablet 1:2.5 ratio (Treatment Arm C) capsule 1:1 ratio (Treatment Arm B) to tablet 1:1 ratio (Treatment Arm D) and tablet 12.5 ratio (Treatment Arm C) to tablet 1:1 ratio (Treatment Arm
D).
Table 30
Anti-Factor Xa Plasma Concentrations (IU/ml) (Standard Deviation shown in parenthesis) ew a [Te [ec [> TT ® | ® oe
BLQ BLQ 0.11 0.06 0.07 0.11 0.07) (0.04) (0.04) (0.08)
BLQ 0.34 0.19 0.10 0.31 0.16 (0.28) (0.14) (0.07) (0.22) (0.16) 45 BLQ 0.32 0.21 0.10 0.42 0.16 (0.22) 0.18) (0.10) (0.33) (0.17)
BLQ 0.28 0.21 BLQ 0.42 0.16 (0.20) (0.18) (0.36) 0.19)
BLQ 0.17 0.13 BLQ 0.31 0.12 (0.14) 0.12) (0.31) 0.17) 120 BLQ 0.11 0.09 BLQ 0.23 0.09 (0.11) (0.08) 0.24) (0.13) * Mean values below 0.05 IU/mL are denoted as below the limit of quantification (BLQ). For statistical purposes, individual values below the limit of quantification (BLQ) were set to 0.025
IU/ml.
[189] These results are shown in Figure 18. . -81- p
Table 31
Plasma anti-Factor Xa Pharmacodynamic Parameters
Treatment Emax, Tmax, hr | EAUC (0- | EAUC (0-
Arm IU/ml (Median last), JU | inf), (IU * (Standard range) * hr/mL) hr/mL)
Deviation) | (Standard (Standard
Deviation) { Deviation)
A 0.00 2.00 0.048 0.258 0.02 (2.00-2.00) 0.38 0.50 0.383 0.689 0.30 (0.50-1.00) (0.295) (0.626)
Cc 0.22 0.75 0.296 0.552 0.18 (0.25-1.00) (0.252) (0.525) 0.11 0.50 1.162 0.297 0.10 (0.25-1.00) (0.145) (0.271)
E 0.44 0.75 0.876 1.563 0.36 (0.50-1.00) (0.729) (1.198)
F 0.17 0.75 0.377 0.621 0.20 (0.25-1.00) (0.394) (0.758)
Table 32 :
Anti-Factor Xa Pharmacodynamic Analysis
Variable Comparison Test (LS | Reference (LS Means) | Difference 90% Confidence
Means) Interval
EAC(0- B-F "0.383 0.338 0.045 -0.148, 0.238
LAST) hr/mL) D-F 0.102 0.338 -0.236 -0.449,-0.024
E-F 0.877 0.338 0.538 0.334, 0.743 0.274 0.197 0.077 -0.469, 0.623 0.877 0.197 0.680 0.131, 1.228 0.877 0.274 0.603 0.406, 0.800 (IU/ml) 0.224 0.175 0.049 0.055, 0.153 0.175 0.268 0.164, 0.372 0.377 0.066 -0.038, 0.170 0.224 0.005 . 0219 0.115, 0.323 0.224 0.106 0.118 0.014, 0.222 B-D | 0377 | 0.106 0271 0.167, 0.375 0.443 0.005 0438 0.334, 0.542
E-C 0.443 0.224 1 0219 0.115, 0.323
[190] As shown in Table 30 and Figure 18, the highest mean concentrations of anti-factor Xa occurred in the following descending order: soft gelatin capsule 1:2.5 ratio (Treatment Arm E), soft gelatin capsule 1:1 ratio (Treatment Arm B), tablet 1:2.5 ratio (Treatment Arm C), liquid SNAC/Heparin dose (Treatment Arm F), tablet 1:1 ratio (Treatment
YT wo2005107773 PCT/US2005/016012
Arm D), and the SNAC control dose (Treatment Arm A). The increase in anti-factor Xa mean concentrations was approximately 2 times higher with the soft gelatin capsule 1.2.5 ratio than with the 1:2.5 tablet and approximately 2.5 times higher than with the liquid references dose.
[191] Based on a 90% confidence interval around the difference for anti-factor
Xa results under a Least Squares Means analysis, the formulation comparisons showing statistically significant differences for EAUC(0-last), the formulation comparisons showing statistically significant differences were soft gelatin capsule 1:2.5 ratio (E) to SNAC control dose (A), capsule 1:2.5 ratio (E) to the liquid reference does (F), capsule 1:2.5 ratio (E) to capsule 1:1 ratio (B), tablet 1:2.5 ratio (C) to tablet 1:1 ratio (D), capsule 1:2.5 ratio (E) to the tablet 1:2.5 ratio (C), and capsule 1:1 ratio (B) to tablet 1:1 ratio (D). The formulation comparisons showing statistically significant differences for Emax were as follows: soft gelatin capsule 1:2.5 ratio (E) and tablet 1:2.5 ratio (C) to SNAC control dose (A), capsule 1:2.5 and 1:1 ratios (E and B) to liquid reference dose (F), tablet 1:2.5 ratio (C) to tablet 1:1 ratio (D), capsule 1:2.5 ratio (E) to tablet 1:2.5 ratio (C), and capsule 1:1 ratio (B) to tablet 1:1 ratio (D). -84 -
AMENDED SHEET
Table 33
Plasma SNAC Pharmacokinetic Parameters
Treatment | Cmax, | Tmax, | AUC (0- | AUC (0- | CL/F, KeL ti, VZ/F
Arm ng/ml hr last), inf), L/br | (Az) (hr) | hr (9) (SD) (SD) "| ng*hr/ml | ng*hr/m! | (SD) (SD) | (SD) (SD) | (SD)
A 5573.1 | 0.50 | 5239.74 | 5448.01 | 227.3 | 0.4903 | 1.50 | 497.5 (2293.9) | (0.25- | (1615.83) | (1604.81) | (61.2) | (0.1395) | (0.33) | (207.0) 2.00) 3041.7 | 0.50 | 2261.17 | 2293.28 {230.0 | 0.8311 | 1.21 | 417.0 (1105.7) | (0.25- | (563.76) | (561.78) | (55.3) | (0.7110) | (0.52) | (229.1) 1.00)
C 6463.3 | 0.25 | 5887.55 | 5977.66 | 206.4 | 0.4820 | 1.55 | 475.2 (4252.6) | (0.25- | (2079.82) | (2056.15) | (46.9) | (0.1371) | (0.45) | (213.6) 1.00) 2481.3 | 0.25 1967.73 | 2002.92 | 260.1 | 0.7755 | 1.35 | 519.2 (1104.0) | (0.25- | (421.50) | (418.81) | (55.6) | (0.7636) | (0.61) | (311.4) 0.50)
E 6539.7 | 0.50 | 5913.98 | 5954.53 | 204.0 | 0.5953 | 1.19 | 351.1 : (3804.8) | (0.25- | (1641.69) | (1633.97) | (44.6) | (0.0861) { (0.17) | (95.1) 1.00)
F 14254.0 | 0.25 13052.1 | 13162.6 | 205.5 | 0.6112 | 1.19 | 361.1 (7153.3) | (0.25- | (4554.21) | (4541.42) | (67.7) | (0.1258) | (0.29) | (181.2) 1.00)
[192] Plasma SNAC concentrations up to 8 hours and 2 hours after : administration are shown in Figures 19 and 20, respectively
[193] In each marker of anti-coagulant activity, capsule formulations produced greater anti-coagulant effect than a similar dose in a tablet formation or the liquid reference dose (90,000 units/2430 mg). In capsule formulations, mean maximum anti-factor Xa concentrations were relatively similar in the 1:1 and 1:2.5 ratio dose groups, at 0.38 and 0.44 IU/mL,
respectively. However EAUC values in the same dose groups were 0.38 and 0.88 IU*hr/mL, respectively, illustrating the longer duration of effect observed in the 1:2.5 ratio dose group.
[194] The soft gelatin capsule produced 2 to 3 fold higher Emax values than the tablet and liquid formulations .
[195] No inherent anti-coagulation activity was demonstrated by the SNAC control dose. All treatments were well tolerated by the subjects.
Example 15
[196] Soft gelatin capsules having the formulations shown in Tables 35a and 35b were prepared by the process described in Example 3, except as indicated below:
Table 352
SNAC 250.00 21.37
Heparin Sodium, USP (15,000 units) "267.18 22.89
Polyethylene Glycol 300, NF (PEG 300) 402.70 34.42
Capmul® PGS 164.00 14.02
Purified Water, USP 81.99
Total weight 1,170.00
Table 35b
Components mg/capsule | % of capsule weight
SNAC 250.0 21.37
Heparin Sodium, USP (25,000 Units) | 267.86 22.89
Polyethylene Glycol 300, NF (PEG 300) | 405.00 34.62
Capmul® PG8 164.00 14.02
Purified Water, USP 81.99
Soybean Oil, USP Super Refined us | 010
Total weight 1,170.00
[197] For the formulation described in Table 35a, Polysorbate 80 was added along with Propylene glycol monocaprylate, purified water, and soybean oil in the stainless steal container, and heparin that was milled through a bead miill with a #140 Mesh screen yielding a heparin particle size of less than 100 microns. Also, the aggregate suspension in the formulation described in Table 35a was milled through a MZ80/A Fryma Colloid mill until the particle size is < 180 microns.
[198] To prepare the formulation in table 35b, Polysorbate 80 was not added with Polyethylene glycol (PEG) 300, Propylene glycol monocaprylate (Capmul® PGS), purified water, and soybean oil. Also, the heparin was milled with a # 80 mesh screen and the suspension was not milled through the colloid mill. The particle size comparison of the formulation of table 35a and table 35b set forth below in table 36
Table 36
Particle Size data for Formulations in Tables 35a and 35b
Formulation in Table 35a Formulation in Table 35b
Suspension (Based on the Target: <= 180 microns Target: <= 180 microns
Grind Gauge) 80 microns (initial aggregate) 200 microns (initial aggregate) 160 microns (final aggregate)
Example 16
[199] The disintegration of the soft gelatin capsules prepared as in Example 15 were determined in three different media, i.e. purified water, 0.1N HCl at pH 1.2 (Simulated
Gastric Fluid w/o pepsin) and 6.8 phosphate buffer (simulated intestinal fluid @ pH 6.8 (w/o pancreatin) at 37 +/- 0.5 °C in a Vankel Disintegration Apparatus model # 35-1000 (Cary, North
Carolina) equipped with a Model 65-2000 Heater Circulator The results are shown below.
Table 37
Disintegration Data
Disintegration Media + Formulation in Table 35a ‘Formulation in Table 35b
Simulated Gastric Fluid @ pH 6 minutes and 15 seconds 4 mins and 31 seconds 1.2 (w/o pepsin)
Simulated Intestinal Fluid @ Not Determined 5 mins and 14 seconds pH 6.8 (w/o pancreatin)
Purified Water 4 mins and 57 seconds
[200] Dissolution profiles for the above two formulations were obtained in a phosphate buffer having pH of 6.8 37 +/- 0.5 °C (Simulated Intestinal Fluid) in the above Vankel
Disintegration Apparatus at 75 RPM. The results for the Formulation shown in Table 35a is shown in Figure 21. The result for the Formulation shown in Table 35b is shown in Figure 22.
Example 17
[201] Soft gelatin capsules having the formulations shown in Table 35a and 35b, prepared as described in Example 15 were administéred to 4 Beagles weighing about 8 kg. The dogs were fasted at least 8 hours prior to dosing and food was returned about 4 hours after dosing of the solid. Each dosage form was delivered to the rear of the mouth by hand. After release of the dosage form, 5 m} of reverse osmosis water was administered into the oral cavity to facilitate swallowing. Following delivery, the oral cavity was inspected to ensure that the solid was swallowed. The study was conducted in cross-over fashion with a one week wash-out period.
[202] Antifactor Xa was measured over a period of about 240 minutes after administration from plasma samples obtained from the jugular, cephalic, or saphenous veins.
Sampling points are rotated.
[203] The results were averaged and are shown in are shown in Figure 23.
Example 18
[204] Soft gelatin capsule having the formulation shown in Table 35a and 35b, prepared as described in Example 15 were administered to 4 Rhesus monkeys (1 capsule/monkey) by the following procedure.
[205] Rhesus monkeys weighing between 5.3 and 6.9 kg were fasted overnight before the experiments and food was returned about 6 hours after dosing of the solid. Each dosage form was delivered to the rear of the mouth using a dosing tune. After release of the dosage form, 5 ml of reverse osmosis water was administered into the oral cavity to facilitate swallowing. Following delivery, the oral cavity was inspected to ensure that the solid was swallowed. The study was conducted in crossover fashion with a one week washout period.
[206] Antifactor Xa was measured over a period of about 400 minutes after administration. CL
[207] The results were averaged and are shown in Figure 24.
Example 19
[208] Soft gelatin capsules having the formulations shown in Table 35a and 35b, prepared as described in Example 15, were administered to 4 beagles in a cross-over design study with a one week washout period. The dogs were fasted overnight before the experiment and food was returned about 2 hours after dosing the solid. Each dosage form was delivered to the rear of the mouth using a pill gun. After release of the dosage form, 5 ml of reverse osmosis water was administered into the oral cavity to facilitate swallowing. Following delivery, the oral cavity was inspected to ensure that the solid was swallowed.
[209] Antifactor Xa activity was measured over a period of about 360 minutes.
The results are set forth in the table 38 below:
Table 38
Antifactor Xa Pharmacokinetic Results
Statistics Formulation | + Dog Coax tmax (min) AUC 5 (IU/mL)
[210] The average Antifactor Xa concentrations over 240 minutes is shown in
Figure 25.
Example 20
[211] Soft gelatin capsules having the formulations shown in Table 35a and 35b, prepared as described in Example 15, were administered to 4 Rhesus Monkeys in across-over design study with a one week washout period. The monkeys were fasted overnight before the experiment and food was returned about 2 hours after dosing the solid. Each dosage form was delivered to the rear of the mouth using a pill gun. After release of the dosage form, 5 ml of :
reverse osmosis water was administered into the oral cavity to facilitate swallowing. Following delivery, the oral cavity was inspected to ensure that the solid was swallowed.
[212] Antifactor Xa activity was measured over a period of about 360 minutes.
The results are set forth in the table 39 below: 93.
AMENDED SHEET
Table 39
Antifactor Xa Pharmacokinetic Results
[213] The above-mentioned patents, applications, test methods, and publications are hereby incorporated by reference in their entirety.
[214] Many variations of the present invention will suggest themselves to those skilled in the art in light of the above detailed description. All such obvious variations are within the fully intended scope of the appended claims. -94 -
AMENDED SHEET
Claims (1)
- We claim:1. A solid pharmaceutical composition comprising: (a) a delivery agent; and (b) wetted heparin.2. The solid pharmaceutical composition of claim 1, wherein the delivery agent is R* © R3 R> OH a H Oo R? OH R' wherein R', R%, R’, and R* are independently hydrogen, -OH, -NR°R’, halogen, C,-C, alkyl, or C,-C, alkoxy; R’ is a substitued or unsubstituted C,-C,, alkylene, substituted or unsubstituted C,- C,, alkenylene, substituted or unsubstituted C,-C,, alkyl(arylene), or substituted or unsubstituted aryl(C,-C,, alkylene); and R® and R’ are independently hydrogen, oxygen, or C,-C, alkyl.3. The solid pharmaceutical composition of claim 2, wherein the delivery agent is selected from N-(8-[2-hydroxybenzoyl]-amino)caprylic acid, N-(10-[2- hydroxybenzoyl]amino)decanoic acid, 8-(N-2-hydroxy-5-chlorobenzoyl)aminocaprylic acid, 8- -95- AMENDED SHEET(N-2-Hydroxy-4-methoxybenzoyl)aminocaprylic acid, 4-[(4-chloro, 2-hydroxybenzoyl)- amino]butanoic acid, pharmaceutically acceptable salts thereof, and mixtures thereof.4. The solid pharmaceutical composition of claim 3, wherein the delivery agent is N-[8-(2-hydroxybenzoyl)amino]caprylic acid or a pharmaceutically acceptable salt thereof.5. The solid pharmaceutical composition of claim 4, wherein the delivery agent is monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate.6. The solid pharmaceutical composition of claim 4, wherein the delivery agent is N-(10-[2-hydroxybenzoyl]amino)decanoic acid, or a pharmaceutically acceptable salt thereof.7. The solid pharmaceutical composition of any of claims 1-6, wherein the heparin in the wetted heparin is selected from unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, and mixtures thereof.8. The solid pharmaceutical composition of any of claims 1-6, wherein the heparin in the wetted heparin is unfractionated heparin.9. The solid pharmaceutical composition of any of claims 1-6, wherein the heparin in the wetted heparin is low molecular weight heparin. - 96 - AMENDED SHEET10. The solid pharmaceutical composition of any of claims 1-6, wherein the heparin in the wetted heparin is very low molecular weight heparin.11. The solid pharmaceutical composition of any of claims 1-6, wherein the heparin in the wetted heparin is ultra low molecular weight heparin.12. The solid pharmaceutical composition of any of claims 1-11, wherein the ratio of the delivery agent to the heparin (mg to USP heparin units) in the wetted heparin ranges from 1:20 to 1:400.13. The solid pharmaceutical composition of any of claims 1-12, wherein the the delivery agent and wetted heparin are gelled together.14. The solid pharmaceutical composition of any of claims 1-13, further comprising a gelling agent.15. The solid pharmaceutical composition of any of claims 1-13, wherein the solid pharmaceutical composition comprises a sufficient amount of delivery agent to cause gelling of the delivery agent and wetted heparin.16. The solid pharmaceutical composition of any of claims 1-13 and 15, wherein the wetted heparin comprises heparin and a wetting agent. -97- AMENDED SHEET© WO 12005/107773 PCT/US2005/01601217. The solid pharmaceutical composition of claim 16, wherein the delivery agent is partially solubilized by the wetting agent.18. A solid dosage form comprising the solid pharmaceutical composition of any of the preceding claims.19. The solid dosage form of claim 18, wherein the solid dosage form is a tablet.20. The solid dosage form of claim 18, wherein the solid dosage form is a capsule.21. The solid dosage form of claim 20, wherein the solid dosage form is a soft gelatin capsule.22. The solid dosage form of claim 20, wherein the solid dosage form is a hard gelatin capsule.23. The solid pharmaceutical composition of any of the preceding claims wherein the dosage of heparin is greater than about 150, 000 IU.24. The solid pharmaceutical composition of claim 23 wherein the dosage of heparin is 15,000 IU to 150,000 IU. -98 - AMENDED SHEET25. The solid pharmaceutical composition of claim 24 wherein the dosage of heparin is 25,000 IU to 90,000 IU.26. The solid pharmaceutical composition of claim 25 wherein the dosage of heparin is 30,000 IU to 80,000 IU.27. The solid pharmaceutical composition of claim 26 wherein the dosage of heparin is 37,500 IU to 75,000 IU.28. The solid pharmaceutical composition of claim 27 wherein the dosage of heparin is about 37,500 IU.29. The solid pharmaceutical composition of claim 27 wherein the dosage of heparin is about 40,000 IU.30. The solid pharmaceutical composition of claim 27 wherein the dosage of heparin is about 50,000 IU.31. The solid pharmaceutical composition of claim 27 wherein the dosage of heparin is about 60,000 IU.32. The solid pharmaceutical composition of claim 27 wherein the dosage of heparin is about 75,000 IU.99. AMENDED SHEET33. The solid pharmaceutical composition of claims 1-32 wherein the dosage of SNAC is less than about 2.4 g.34. The solid pharmaceutical composition of claim 33 wherein the dosage of SNAC is less than about 2.2 g.35. The solid pharmaceutical composition of claim 34 wherein the dosage of SNAC is less than about 1.8 g.36. The solid pharmaceutical composition of claim 35 wherein the dosage of SNAC is less than about 1.2 g.37. The solid pharmaceutical composition of claim 36 wherein the dosage of SNAC is less than about 1 g.38. The solid pharmaceutical composition of claim 37 wherein the dosage of SNAC is less than about .9 g.39. The solid pharmaceutical composition of claim 38 wherein the dosage of SNAC is less than about .8 g.40. The solid pharmaceutical composition of claim 39 wherein the dosage of SNAC is less than about .7 g. - 100 - AMENDED SHEET41. The solid pharmaceutical composition of claim 40 wherein the dosage of SNAC is less than about .6 g.42. The solid pharmaceutical composition of claim 41 wherein the dosage of SNAC is less than or equal to about .5 g.43. The solid pharmaceutical composition of claims 1-32 wherein the dosage of SNAC is 50 mgto 2.4 g.44. The solid pharmaceutical composition of claim 43 wherein the dosage of SNAC is 100 mgto 1.2 g.45. The solid pharmaceutical composition of claim 44 wherein the dosage of SNAC is 900 mgto 1.2 g.46. The solid pharmaceutical composition of claim 45 wherein the dosage of SNAC is about 1.15 g.47. The solid pharmaceutical composition of claim 44 wherein the dosage of SNAC is 125mgto 1g.48. The solid pharmaceutical composition of claim 47 wherein the dosage of SNAC is 250 mg to 750 mg. - 101 - AMENDED SHEET49. The solid pharmaceutical composition of claim 48 wherein the dosage of SNAC is 400 mg to 600 mg.50. The solid pharmaceutical composition of claim 49 wherein the dosage of SNAC is about 500 mg.51. Use of the solid pharmaceutical composition or dosage form of any of the preceding claims in the manufacture of a medicament for administering heparin to an animal.52. Use of an effective amount of the solid pharmaceutical composition or dosage form of any of claims 1-50 in the manufacture of a medicament for treating or preventing thrombosis in an animal.53. The use of claim 52, wherein the thrombosis is deep vein thrombosis or pulmonary embolism.54. The use of claims 51 or 52 wherein said effective amount is sufficient to increase the aPTT by at least about 100% as compared to an untreated state of the same subject.55. The use of claim 54 wherein said effective amount is sufficient to increase the aPTT by at least about 150% as compared to an untreated state of the same subject.56. The use of claim 55 wherein said effective amount is sufficient to increase the aPTT by at least about 165% as compared to an untreated state of the same subject. - 102 - AMENDED SHEET57. The use of claim 56 wherein said effective amount is sufficient to increase the aPTT by at least about 200% as compared to an untreated state of the same subject.58. The use of claims 51 - 57 wherein said effective amount is sufficient to increase the AntiFactor Xa to .05to .4 IU/ml.59. The use of claim 58 wherein said effective amount is sufficient to increase the AntiFactor Xa to .15to .35 IU/ml.60. The use of claim 59 wherein said effective amount is sufficient to increase the AntiFactor Xato .15to .20 IU/ml.61. The use of claim 60 wherein said effective amount is sufficient to increase the AntiFactor Xa to about .2 IU/ml.62. The use of claims 51 - 57 wherein said effective amount is sufficient to increase the AntiFactor Xa to greater than about .05 IU/ml.63. The use of claim 62 wherein said effective amount is sufficient to increase the AntiFactor Xa to greater than about .1 IU/ml. -103 - AMENDED SHEET64. The use of claim 63 wherein said effective amount is sufficient to increase the AntiFactor Xa to greater than about .15 IU/ml.65. A method of preparing a solid dosage form of wetted heparin comprising the steps of: (a) blending a delivery agent and heparin; (b) adding the delivery agent and heparin to a wetting agent to obtain a composition containing wetted heparin.66. The method of claim 65, wherein the heparin in the wetted heparin is selected from unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, and mixtures thereof.67. The method of claim 65, wherein the heparin in the wetted heparin is unfractionated heparin.68. The method of claim 65, wherein the heparin in the wetted heparin is low molecular weight heparin.69. The solid dosage form of claim 65, wherein the heparin in the wetted heparin is very low molecular weight heparin. - 104 - AMENDED SHEET70. The method of claim 65, wherein the heparin in the wetted heparin is ultra low molecular weight heparin.71. A method of improving the bioavailability of a solid heparin dosage form containing unwetted heparin, comprising the step of: (a) substituting the unwetted heparin in the dosage form with wetted heparin.72. The method of claim 71, wherein the heparin in the wetted heparin is selected from unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, and mixtures thereof.73. The method of claim 71, wherein the heparin in the wetted heparin is unfractionated heparin.74. The method of claim 71, wherein the heparin in the wetted heparin is low molecular weight heparin.75. The method of claim 71, wherein the heparin in the wetted heparin is very low molecular weight heparin. © 76. The method of claim 71, wherein the heparin in the wetted heparin is ultra low molecular weight heparin. - 105 - AMENDED SHEET77. Use of an effective amount of the solid pharmaceutical composition or dosage form of any of claims 1-50 in the manufacture of a medicament for preventing thrombosis In an animal.78. The use of claim 77, wherein the thrombosis is deep vein thrombosis or pulmonary embolism.79. The use of claims 77 or 78 wherein said effective amount is sufficient to increase the aPTT by less than or equal to about 10% as compared to an untreated state of the same patient.80. The use of claim 79 wherein said effective amount is sufficient to increase the aPTT by about 10% .81. The use of claim 80 wherein no or a decreased number of thrombosis is seen as compared to an untreated patient.82. The use of claims 77 or 78 wherein said effective amount is sufficient to increase the aPTT by more than about 10% as compared to an untreated state of the same patient.83. The use of claims 77 - 82 wherein said effective amount is sufficient to increase the AntiFactor Xa to 0.05to .4 IU/ml.84. The use of claim 83 wherein said effective amount is sufficient to increase the AntiFactor Xato .15to .35 IU/ml. - 106 - AMENDED SHEET85. The use of claim 84 wherein said effective amount is sufficient to increase the AntiFactor Xa to about .25 IU/ml.86. The use of treating thrombosis in an animal of any of the preceding claims wherein said animal is a mammal.87. The use of treating thrombosis in a mammal of claim 86 wherein said mammal is a human.88. The use of preventing thrombosis in an animal of any of the preceding claims wherein said animal is a mammal.89. The use of preventing thrombosis in a mammal of claim 88 wherein said mammal is a human.90. A solid pharmaceutical composition comprising: (a) SNAC, and (b) wetted heparin, wherein: (1) 120 minutes after oral administration of the solid pharmaceutical composition to a human, the human exhibits a plasma aPTT, an anti-factor Ila plasma concentration, an anti-factor - 107 - AMENDED SHEETXa plasma concentration, or any combination of the foregoing that are statistically significantly greater than that 120 minutes after oral administration of an identical composition containing unwetted heparin instead of wetted heparin, or 2) after oral administration of the solid pharmaceutical composition to a human, the human exhibits an Emax for aPTT, EAUC(0-inf) for aPTT, Emax for anti-factor Ila, EAUC(O- inf) for anti-factor Ila, Emax for anti-factor Xa, EAUC(0-inf) for anti-factor Xa, or any combination of the foregoing that are statistically significantly greater than after oral administration of an identical composition containing unwetted heparin instead of wetted heparin, or 3) both.91. The solid pharmaceutical composition of claim 90, wherein the heparin in the wetted heparin is selected from unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, and mixtures thereof.92. The solid pharmaceutical composition of claim 90, wherein the heparin in the wetted heparin is unfractionated heparin.93. The solid pharmaceutical composition of claim 90, wherein the heparin in the wetted heparin is low molecular weight heparin.94. The solid pharmaceutical composition of claim 90, wherein the heparin in the wetted heparin is very low molecular weight heparin. - 108 - AMENDED SHEET95. The solid pharmaceutical composition of claim 90, wherein the heparin in the wetted heparin is ultra low molecular weight heparin.96. A solid pharmaceutical composition comprising: (a SNAC, and (b) wetted heparin, wherein: (1) 120 minutes after oral administration of the solid pharmaceutical composition to a human, the human exhibits one or more of the following: (i) a plasma aPTT of at least about 38 seconds, (ii) an anti-factor IIa plasma concentration of at least 0.11 IU/ml, or (iii) an anti-factor Xa plasma concentration of at least 0.1 IU/ml, 2) after oral administration of the solid pharmaceutical composition to a human, the human exhibits one or more of the following: (1) an Emax for aPTT of at least about 50 IU/ml, (ii) an EAUC(0-inf) for aPTT of at least about 80 IU * hr/ml, (iii) an Emax for anti-factor Ila of at least about 0.35 IU/ml, (iv) an EAUC(0-inf) for anti-factor Ila of at least about 0.7 IU * hr/ml, (v) an Emax for anti-factor Xa of at least about 0.35 IU/ml, (vi) an EAUC(0-inf) for anti-factor Xa of at least about 0.68 1U * hr/ml, or 3) both.97. The solid pharmaceutical composition of claim 96, wherein the human exhibits a plasma aPTT of at least about 39 seconds. - 109 - AMENDED SHEET+ ‘98. The solid pharmaceutical composition of claim 96, wherein the human exhibits a plasma aPTT of at least about 50 seconds.99. The solid pharmaceutical composition of claim 96, wherein the human exhibits an anti-factor Ila plasma concentration of at least about 0.2 IU/ml.100. The solid pharmaceutical composition of claim 96, wherein the human exhibits an anti-factor Xa plasma concentration of at least about 0.2 IU/ml.101. The solid pharmaceutical composition of claim 96, wherein the human exhibits an EAUC(0-inf) for aPTT of at least about 100 IU * hr/ml.102. The solid pharmaceutical composition of claim 96, wherein the human exhibits an EAUC(0-inf) for aPTT of at least about 150 IU * hr/ml.103. The solid pharmaceutical composition of claim 96, wherein the human exhibits an EAUC(0-inf) for aPTT of at least about 180 IU * hr/ml.104. The solid pharmaceutical composition of claim 81, wherein the human exhibits an Emax for anti-factor Ila of at least about 0.4 IU/ml.105. The solid pharmaceutical composition of claim 96, wherein the human exhibits an EAUC(0-inf) for anti-factor IIa of at least about 1.0 IU * hr/ml. -110 - AMENDED SHEETPy ‘y )106. The solid pharmaceutical composition of claim 96, wherein the human exhibits an Emax for anti-factor Xa of at least about 0.4 IU/ml.107. The solid pharmaceutical composition of claim 96, wherein the human exhibits an EAUC(0-inf) for anti-factor Xa of at least about 1.0 IU * hr/ml.108. The solid pharmaceutical composition of any of claims 96-107, wherein the heparin in the wetted heparin is selected from unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, and mixtures thereof.109. The solid pharmaceutical composition of any of claims 96-107, wherein the heparin in the wetted heparin is unfractionated heparin.110. The solid pharmaceutical composition of any of claims 96-107, wherein the heparin in the wetted heparin is low molecular weight heparin.111. The solid pharmaceutical composition of any of claims 96-107, wherein the heparin in the wetted heparin is very low molecular weight heparin.112. The solid pharmaceutical composition of any of claims 96-107, wherein the heparin in the wetted heparin is ultra low molecular weight heparin. - 111 - AMENDED SHEET113. Use of one or more solid pharmaceutical compositions comprising SNAC and wetted heparin in the manufacture of a medicament for use in a method of treating or preventing DVT in a human in need thereof, the method comprising orally administering the one or more solid pharmaceutical compositions comprising SNAC and wetted heparin, wherein (DH 120 minutes after oral administration of the solid pharmaceutical composition to a human, the human exhibits one or more of the following: (i) a plasma aPTT of at least about 38 seconds, (ii) an anti-factor Ila plasma concentration of at least about 0.11 IU/ml, or (iii) an anti-factor Xa plasma concentration of at least about 0.1 IU/ml, 2) after oral administration of the solid pharmaceutical composition to a human, the human exhibits one or more of the following: (i) an Emax for aPTT of at least about 50 IU/ml, (ii) an EAUC(0-inf) for aPTT of at least 80 IU * hr/ml, (iii) an Emax for anti-factor Ila of at least about 0.35 IU/ml, (iv) an EAUC(0-inf) for anti-factor Ila of at least about 0.7 IU * hr/ml, (v) an Emax for anti-factor Xa of at least about 0.35 [U/ml, (vi) an EAUC(0-inf) for anti-factor Xa of at least about 0.68 IU * hr/ml, or 3) both.114. The use of claim 113, wherein the human exhibits a plasma aPTT of at least about 39 seconds.115. The use of claim 113, wherein the human exhibits a plasma aPTT of at least about 50 seconds. - 112 - AMENDED SHEET116. The use of claim 113, wherein the human exhibits an anti-factor Ila plasma concentration of at least about 0.2 IU/ml.117. The use of claim 113, wherein the human exhibits an anti-factor Xa plasma concentration of at least about 0.2 IU/ml.118. The use of claim 113, wherein the human exhibits an EAUC(0-inf) for aPTT of at least about 100 IU * hr/ml.119. The use of claim 113, wherein the human exhibits an EAUC(0-inf) for aPTT of at least about 150 IU * hr/ml.120. The use of claim 113, wherein the human exhibits an EAUC(0-inf) for aPTT of at least about 180 IU * hr/ml.121. The use of claim 113, wherein the human exhibits an Emax for anti-factor IIa of at least about 0.4 IU/ml.122. The use of claim 113, wherein the human exhibits an EAUC(0-inf) for anti-factor Ila of at least about 1.0 IU * hr/ml.123. The use of claim 113, wherein the human exhibits an Emax for anti-factor Xa of at least about 0.4 IU/ml. -113 - AMENDED SHEET- IY124. The use of claim 113, wherein the human exhibits an EAUC(0-inf) for anti-factor Xa of at least about 1.0 IU * hr/ml.125. The use of any of claims 113-124, wherein the heparin in the wetted heparin is selected from unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, and mixtures thereof.126. The use of any of claims 113-124, wherein the heparin in the wetted heparin is unfractionated heparin.. 127. The use of any of claims 113-124, wherein the heparin in the wetted heparin is low molecular weight heparin.128. The use of any of claims 113-124, wherein the heparin in the wetted heparin is very low molecular weight heparin.129. The use of any of claims 113-124, wherein the heparin in the wetted heparin is ultra low molecular weight heparin.130. A solid pharmaceutical composition substantially as herein exemplified with reference to any one of Examples 1, 3, 4, 6 to 8 and 15. -114 - AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56947504P | 2004-05-06 | 2004-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200609809B true ZA200609809B (en) | 2008-04-30 |
Family
ID=38083441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200609809A ZA200609809B (en) | 2004-05-06 | 2006-11-24 | Solid dosage form of wetted heparin |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1964724A (en) |
ZA (1) | ZA200609809B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108344875B (en) * | 2017-01-22 | 2021-11-02 | 上海长岛生物技术有限公司 | Method for improving sensitivity of reagent for activating partial thromboplastin time to heparin and application |
WO2023102690A1 (en) * | 2021-12-06 | 2023-06-15 | Guangzhou Dazhou Biomedicine Ltd. | Oral delivery of heparins |
-
2005
- 2005-05-06 CN CN 200580018507 patent/CN1964724A/en active Pending
-
2006
- 2006-11-24 ZA ZA200609809A patent/ZA200609809B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1964724A (en) | 2007-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005240206B2 (en) | Solid dosage form of wetted heparin | |
EP1441713B1 (en) | Modified release tamsulosin tablets | |
US20180338923A1 (en) | Formulations for delivering insulin | |
KR101687781B1 (en) | Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders | |
CN107308125B (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
KR20110097936A (en) | Ulipristal acetate tablets | |
KR20040018333A (en) | Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders | |
CA2679782A1 (en) | Oral administration of a calcitonin | |
JP6276287B2 (en) | Fexofenadine-rich solid unit and process for producing the same | |
AU2011276450A1 (en) | Pharmaceutical compositions containing vanoxerine | |
WO2012113117A1 (en) | Oral preparation comprising protein or polypeptide, preparation method thereof, and use thereof | |
ZA200609809B (en) | Solid dosage form of wetted heparin | |
KR20150003726A (en) | Prasugrel-Containing Immediate Release Stable Oral Pharmacetical Compositions | |
WO2021185265A1 (en) | Oral pharmaceutical composition | |
US20050123615A1 (en) | Controlled release dosage forms of azithromycin | |
WO2013147135A1 (en) | Controlled-release pharmaceutical composition | |
EP2197423B1 (en) | Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof | |
CN109806271B (en) | Pharmaceutical composition for treating allergic dermatitis and preparation thereof | |
JP2005508369A (en) | Microcapsule matrix microspheres, pharmaceutical compositions and methods for promoting absorption | |
CN111714469B (en) | Thymalfasin preparation and preparation method thereof | |
WO2024043842A1 (en) | Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients | |
JP2023507430A (en) | Pharmaceutical compounds containing N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide Composition | |
CN113730356A (en) | Ticagrelor pharmaceutical composition, and preparation method and application thereof | |
CN117771248A (en) | Ezetimibe rosuvastatin calcium preparation and preparation method thereof | |
CN117715625A (en) | Intra-articular injection dosage form comprising colchicine for the treatment of crystalline and amorphous-related acute inflammatory arthritis |